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Zusammenfassung 
Das zentrale Nervensystem (ZNS) wurde lange Zeit als Ort eingeschränkter 
Immunüberwachung beschrieben. Allerdings stellt das ZNS ein strukturell stark 
unterteiltes Organ dar, welches aus dem Parenchym, den Ventrikeln, den verschiedenen 
Hirnhautschichten und aus mehreren dazwischenliegenden Barrieren besteht. In all 
diesen Strukturen befinden sich verschiedene Immunzellen, die unterschiedliche Rollen 
in der Überwachung von Geweben, in der Homöostase von Neuronen, der 
Immunabwehr, sowie in neurologischen Erkrankungen spielen.  
Trotz der Bedeutung ZNS-residenter Immunzellen sind unsere Möglichkeiten diese 
Populationen zu charakterisieren und somit ihre unterschiedlichen Funktionen zu 
verstehen erheblich eingeschränkt. Eine eindeutige Unterscheidung zwischen den 
verschiedenen Immunzellen innerhalb des ZNS hing bisher überwiegend von 
Bildgebungsverfahren ab, bei denen die spezifische Zellform und deren Lokalisation 
zur Identifikation der Zellen diente. Darüber hinaus reagieren diese Zellen während 
einer Erkrankung des ZNS, was üblicherweise durch die Veränderung ihrer 
Morphologie beschrieben wird. Dies ist jedoch oftmals nicht eindeutig und erschwert 
somit die Unterscheidung zwischen verschiedenen ZNS-residenten Zelltypen und aus 
dem Blut einwandernden Zellen.  
In dieser Arbeit setzen wir hochdimensionale Massen- und Durchflusszytometrie in 
Kombination mit Algorithmus-basierter Analyse ein, um ZNS Immunzellen auf 
unvoreingenommene Weise zu analysieren. Wir konnten alle im normalen ZNS der 
Maus vorkommenden Immunzelltypen eindeutig identifizieren und des weiteren die 
Existenz neuer Untergruppen von sogenannten “Border-assoziierten Makrophagen“ 
(BAMs) und deren spezifische Lokalisation nachweisen. Außerdem untersuchten wir 
verschiedene Formen von ZNS-Erkrankungen die beispielsweise im erhöhten Alter 
oder in Mausmodellen für Alzheimer und Multiple Sklerose eintreten und konnten 
sowohl krankheitsspezifische als auch krankheitsübergreifende Eigenschaften von 
Mikrogliazellen und BAMs identifizieren. Zusammengefasst tragen unsere 
Erkenntnisse somit zum Verständnis der Immunzelllandschaft des ZNS bei und stellen 
eine wichtige Ressource für die Erforschung von ZNS Krankheitsmechanismen, 
potentieller Biomarker und neuen Zielobjekten in der therapeutischen Behandlung dar.  
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Summary 
The central nervous system (CNS) was long regarded as a site of limited immune 
surveillance. However, the CNS is a compartmentalized organ comprising the 
parenchyma, the ventricles containing the choroid plexus and cerebrospinal fluid, the 
meningeal layers which envelop the parenchyma, and several ‘absolute’ and semi-
permeable barriers. Within these compartments are located various CNS-resident 
immune cell types with diverse roles in tissue surveillance, neuronal and brain tissue 
homeostasis, immune defense and neurological diseases.  
Despite the importance of CNS-resident immune cells, our ability to fully characterize 
these populations and subsequently to understand their distinct functions has thus far 
been severely limited. Reliable discrimination between different immune cells within 
the CNS has largely depended on imaging techniques where their distinct patterns of 
localization provide a surrogate for their identification. Furthermore, during CNS 
pathology, CNS-resident immune cells become reactive. Reactive cells were commonly 
described by their morphological changes. However, these changes were often 
ambiguous, presenting a challenge in differentiating types of reactive CNS-resident 
cells as well as differentiating them from infiltrating blood-derived cells during 
neuroinflammatory diseases. 
In order to overcome localization- and morphology-dependent limitations, we applied 
high-dimensional single-cell mass and fluorescence cytometry combined with 
algorithm-guided analysis. These techniques allow for the multiplexing of cell-
identifying protein markers to an unprecedented scale and the unbiased analysis of 
immune cell populations. We unambiguously identified all the immune cells within the 
normal murine CNS and uncovered the existence of novel subsets within CNS border-
associated macrophages (BAMs), further showing their enrichment in specific CNS 
compartments. We extended our analysis to different forms of CNS pathology, 
including aging and murine models for Alzheimer’s disease and Multiple Sclerosis. We 
revealed that microglia, the main immune cells of the CNS, and BAMs exhibit disease-
specific and -unspecific reactivity across CNS pathologies. Together, these data add to 
our understanding of the immune landscape of the CNS and provide a powerful 
resource for the study of CNS disease mechanisms, potential biomarkers and 
therapeutic targets.  
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1. Introduction 
1.1. The central nervous system has compartmentalized immune privilege 
The central nervous system (CNS) is a highly compartmentalized organ which is 
protected by a series of layers and barriers that shield it from blood-borne pathogens 
and other threats, including potentially harmful inflammatory mediators. The brain 
itself was long regarded as a site of limited immune surveillance due to the lack of 
obvious lymphatic vessels, the presence of the blood brain barrier (BBB), and slow 
transplant rejection (Murphy and Sturm, 1923; Shirai, 1921). Thus, the functional 
contribution of the peripheral immune system to CNS homeostasis and neurological 
diseases was disregarded and the organ was considered to be “immune privileged”. 
However, more sophisticated examination of the CNS by later studies revealed that the 
level of steady state immune privilege varies dramatically between compartments and 
is only really applicable to the parenchyma proper where neurons are found (Matyszak 
and Perry, 1996a). The meninges, perivascular spaces surrounding parenchymal blood 
capillaries, and the choroid plexus, contained within the brain ventricles, are not 
immune-restricted and harbor a variety of tissue resident leukocytes (Herz et al., 2017). 
 
1.2. Protective borders and barriers separate CNS compartments 
1.2.1. Meningeal layers 
The different CNS compartments are separated by several ‘absolute’ and semi-
permeable barriers (Shechter et al., 2013b). The meninges represent the first type of 
barrier (Figure I, a), located on the surface of the brain, and comprise three distinct 
layers: the thick dura mater on top, followed by the delicate, web-like arachnoid mater, 
shielding the CSF-containing subarachnoid space (SAS) which lies above the thin pia 
mater that intimately envelops the parenchyma across its entire convoluted surface area. 
The leptomeninges is defined as the layer of pia mater, SAS and arachnoid mater. The 
level of exclusion from the periphery increases with depth from the top down. The dura 
mater harbors arteries and veins which lack a proper BBB and are fenestrated rather 
than continuous. Further establishing the dura mater as connected to the periphery, 
recent studies in mice (Aspelund et al., 2015; Louveau et al., 2015), nonhuman primates 
and humans (Absinta et al., 2017) demonstrated that a lymphatic system lines the dural 
sinuses and drains fluid, macromolecules and immune cells from the CNS to the deep 
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cervical lymph nodes. The arachnoid mater is impermeable to fluids, forming a barrier 
that separates and shields the SAS containing the CSF from the dura mater. The pia 
mater separates the SAS from the parenchyma in the brain and spinal cord and also 
surrounds the SAS-blood vessels which emerge from the parenchyma, creating a blood-
leptomeningeal barrier of tight-junction connected epithelial cells (Engelhardt et al., 
2017).  
 
1.2.2. Parenchyma and perivascular spaces 
The second barrier, the BBB, is the strongest barrier against contact with the periphery 
and is only found in the parenchymal and leptomeningeal capillaries (Figure I, b). The 
BBB is formed mainly by the endothelial cells of the blood vessels which are connected 
by tight junctions and responsible for the controlled entry of solutes, molecules and 
ions into the brain parenchyma (Ransohoff and Engelhardt, 2012). The extravasation 
of immune cells is possible, but in steady state this only happens at the level of 
postcapillary venules where CSF filled perivascular spaces are present and where the 
further penetration of immune cells into the CNS parenchyma is blocked by the glia 
limitans (Owens et al., 2008). The glia limitans is a barrier formed by the association 
of astrocyte endfeet to the vascular basement membrane of the capillaries, it also covers 
the entire surface of the brain and spinal cord and is continuous with the subarachnoid 
space (Owens et al., 2008; Ransohoff and Engelhardt, 2012). 
 
1.2.3. Choroid plexus 
Lastly, a third barrier is formed by the epithelial cells of the choroid plexus (the blood-
CSF barrier, Figure I, c), which generates the CSF and controls the movement of 
molecules between the blood and the CSF (Daneman & Engelhardt, 2017). The choroid 
plexus has also been proposed to regulate the passage of immune cells into the CSF, 
and is therefore considered the main site of immune surveillance within the CNS 
(Engelhardt et al., 2016). The choroid plexus stroma, however, is supplied by blood 
vessels that do not present a BBB and therefore solutes and immune cells can pass from 
the blood into the choroid plexus stroma (Engelhardt et al., 2017).  
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Figure I. The compartments of the CNS are separated by absolute and semi-permeable 
barriers. (a) Dura mater is supplied by meningeal arteries (MA) and veins (MV), and dural 
microvessels lack a BBB; the dura mater also contains lymphatics (ML). The dura is 
immediately adjacent to the arachnoid mater, which forms the outer blood-CSF barrier of the 
SAS. The pia mater coats veins and arteries in the SAS and surrounds arteries entering the brain 
forming the blood-leptomeningeal barrier. The glia limitans forms a barrier at the surface of the 
CNS parenchyma and around blood vessels. (b) Highly specialized BBB endothelial cells are 
coated by a basement membrane formed by the fusion of endothelial and glia limitans basement 
membranes. Pericytes are embedded in the endothelial basement membrane. CNS microvessels 
are surrounded by the glia limitans, which is composed of the parenchymal basement 
membrane and astrocyte end-feet. At postcapillary venules, the adjacent basement membranes 
leave a virtual perivascular space in which occasional APCs are embedded. (c) Choroid plexus 
epithelial cells establish the blood-CSF barrier. The choroid plexuses are localized in the 
ventricles of the brain and produce CSF. The choroid plexus stroma harbors DCs and 
macrophages and is supplied by a dense microvascular network that does not establish a BBB. 
(d) Schematic coronal brain section depicting the localization of the brain barriers. (Engelhardt 
et al., 2017, Nature Immunology.) 
 
1.3. Immune sentinels within the CNS 
1.3.1. Microglia 
The parenchyma is the most protected and isolated compartment within the CNS, 
however it does host an important sentinel tissue-resident macrophage population: the 
microglia. As with tissue-resident macrophages in other organs throughout the body, 
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microglia develop from yolk-sac erythromyeloid progenitors and are seeded into the 
brain during embryogenesis on E8.5-E9 (embryonic day) in mice. This occurs before 
the establishment of the BBB, after which the brain is disconnected from the periphery 
and becomes “immune privileged” (Ginhoux et al., 2010). After brain colonization in 
the steady state, microglia are maintained by self-renewal without contribution from 
bone marrow monocytes (Ajami et al., 2007).  
Microglia possess motile processes which form their characteristic branched 
morphology and are used to survey the parenchymal environment across long distances 
(Nimmerjahn et al., 2005). Disturbances in brain homeostasis can cause rapid and 
profound changes in microglial morphology, gene expression and function. Microglia 
were shown to actively move toward sites of tissue damage where they are involved in 
the elimination of debris after neuronal cell death (Hanisch and Kettenmann, 2007). 
Being immune cells, microglia are able to respond to infectious threats and recruit other 
immune cells to the brain to fight the infection. However, they also have important roles 
in the healthy and developing brain. Here they contribute to vascular formation 
(Checchin et al., 2006), alter neuronal circuits, phagocytose apoptotic neurons, 
contribute to synaptic maturation and pruning (Paolicelli et al., 2011; Roumier et al., 
2004; Salter and Beggs, 2014; Tremblay et al., 2010). Furthermore, microglial 
depletion was shown to negatively influence the development of social interaction and 
impair learning abilities (Parkhurst et al., 2013; Zhan et al., 2014). The crucial 
surveying function of neuronal and synaptic homeostasis by microglia suggests that 
they also have important roles in neurodegenerative diseases. Indeed, there is mounting 
evidence linking microglia to the progression and pathogenesis of neurodegenerative 
diseases, however their exact contribution remains unclear and is further discussed 
below (Colonna and Butovsky, 2017; Prinz and Priller, 2014). 
 
1.3.2. CNS border-associated macrophages: BAMs 
Outside the brain parenchyma but within the CNS compartments, immune surveillance 
is thought to be mediated by rare populations of dendritic cells (DCs) as well as the 
more abundant macrophages. These macrophages line the meninges, choroid plexus 
and perivascular spaces (Bechmann et al., 2001; Goldmann et al., 2016; McMenamin, 
1999). Since they are found within the border regions of the CNS and not within the 
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parenchyma, they can be called CNS “border-associated macrophages” (BAMs). For a 
long time, BAMs were thought to be bone-marrow derived cells. However, and 
similarly to early studies on the ontogeny of microglia, the majority of studies on BAM 
ontogeny were based on irradiation models and administration of chemotherapeutic 
drugs to deplete bone-marrow derived leukocytes (Aguzzi et al., 2013). These depletion 
approaches were responsible for an induced and artificial replacement of macrophages 
from blood monocytes, mostly because of the disruption of the BBB and production of 
chemo-attractants (Kierdorf et al., 2013; Mildner et al., 2007). Recent work using 
inducible fluorescent reporter proteins on macrophage progenitors, thus allowing for 
cell fate-mapping during embryogenesis, has elegantly shown that BAMs are actually 
seeded during development. Most likely they are seeded from the yolk sac but with a 
possible contribution from the fetal liver, and in that way they are similar to microglia 
and other tissue-resident macrophages (Goldmann et al., 2016) (Figure II). Goldmann 
and colleagues further demonstrated that BAMs that colonize the meninges and 
perivascular spaces are self-renewing and stable, while choroid plexus BAMs are 
slowly replaced from CCR2+ blood monocytes. 
 
Figure II. Ontogeny of border-associated macrophages (BAMs) of the CNS. Adult 
microglia are derived exclusively from yolk sac progenitors. Perivascular and meningeal BAMs 
arise from embryonic precursors, most probably from yolk sac macrophage progenitors, with a 
potential contribution from fetal liver monocytes. Choroid plexus BAMs have a heterogeneous 
origin that encompasses adult bone marrow monocytes and embryonic precursors. (Greter, 
2016, Nature Immunology). 
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While our knowledge on the complete functions of microglia in homeostasis and 
disease is still lacking, it is far ahead of what we know about the role of BAMs within 
the CNS, which is so far mostly based on speculation and hypothesis.  
General macrophage functions throughout the body range from scavenger and 
professional phagocyte to tissue homeostasis and repair, remodeling of the extra-
cellular matrix and angiogenesis. They have also been shown to maintain immune 
tolerance in the testes (Mossadegh-Keller et al., 2017) as well as in tumor 
microenvironments as highly problematic tumor-associated macrophages (TAMs) 
(Davies et al., 2013; Wynn et al., 2013). Heterogeneity within macrophage populations 
was initially described as a binary polarization profile based on an inflammatory (M1) 
and tolerogenic (M2) phenotype (Sica and Mantovani, 2012), defined by responses to 
the cytokine IFN-g and activation of toll-like receptors (TLRs), or to IL-4 and IL-13 
cytokines, respectively. However, this generalized categorization has since been proven 
inadequate as macrophages exist with a range of phenotypes and functional potential 
between the two extremes of M1 and M2. Transcriptional profiling of tissue-resident 
macrophages by the Immunological Genome Project showed that these populations 
have high transcriptional diversity with minimal overlap, suggesting that the many 
faces of the macrophage represent many unique classes (Gautier et al., 2012). In fact, 
macrophages are highly plastic cells which seem to adapt their identity and functional 
capacity according to largely uncharacterized niche-specific stimuli within their local 
microenvironments. Thus, it is logical to speculate that the function of BAMs may 
depend on their compartmental location within the CNS. 
Early studies in the rat brain show that perivascular BAMs of the CNS are able to take 
up macromolecules injected into the blood stream or into brain ventricles, thus 
demonstrating their scavenger function (Kida et al., 1993; Mato et al., 1996). Like 
microglia, perivascular BAMs may play a role in blood vessel formation, however the 
distinction between microglia and perivascular BAMs was not clear in this study 
(Checchin et al., 2006). Another study demonstrated that perivascular and meningeal 
BAMs show early signs of activation in experimental allergic encephalomyelitis, 
preceding parenchymal invasion by peripheral leukocytes. Their depletion by 
stereotaxic injection of clodronate-containing liposomes into the fourth ventricle 
resulted in less severe disease symptoms (Polfliet et al., 2002), implying that they play 
a role in initiation of inflammation within the CNS. Applying the same liposome-
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clodronate method in a mouse model for Alzheimer's disease (AD), perivascular BAM 
depletion was associated with a defective clearance of amyloid-β (Aβ) peptides in 
leptomeningeal and cortical blood vessels, in a phenomenon called cerebral amyloid 
angiopathy (Hawkes and McLaurin, 2009). BAMs were found to associate with β-
amyloid peptides while microglia and astrocytes were not, thereby suggesting that the 
scavenger function of perivascular BAMs extends to potentially pathogenic proteins 
and could be harnessed in the treatment of proteopathies like AD and Parkinson’s 
disease.  
Importantly, BAMs have been shown to express MHCII in the steady state (Matyszak 
et al., 1992; McMenamin, 1999) while microglia do not, and because of their strategic 
locations at CNS interfaces, BAMs are thought to be competent CNS antigen presenting 
cells (APCs) (Becher et al., 2006; Prinz et al., 2017). This theory was strengthened 
when T cells were shown to interact with pial BAMs, allowing them to enter the CNS 
parenchyma during neuroinflammation (Schläger et al., 2016). However, the majority 
of these studies mainly based their conclusions on microscopy-based identification of 
cell types, in which the distinction between BAMs and microglia or DCs was unclear. 
Therefore, an unambiguous characterization of BAMs is necessary to understand and 
study their functions in both CNS homeostasis and disease.  
 
1.3.3. CNS-resident dendritic cells 
Classical DCs do not develop as early as tissue-resident macrophages but arise from 
precursors (pre-DCs) in the adult bone marrow. They have a relatively short life span 
of 1-2 weeks, are therefore constantly replenished from the bone marrow and their 
primary function is professional antigen presentation (Liu et al., 2009; Liu et al., 2007). 
DCs and macrophages (as well as neutrophils) are both professional phagocytes and 
surveyors, they both accumulate at sites of pathogen entry and are both capable of 
presenting antigen. However, DCs are highly specialized sensing and stimulating cells 
and the most efficient APCs. DCs phagocytose and process antigen, preserving “useful” 
material which is loaded onto MHCI and MHCII molecules with which DCs are the 
only APCs able to stimulate naïve and memory T cells (Savina and Amigorena, 2007). 
DCs are also patrollers. Migratory DCs patrol non-lymphoid tissues for antigen and 
migrate to lymphoid organs to stimulate adaptive immune responses, while 
	8	
macrophages are more non-migratory sentinel cells. Furthermore, DCs are remarkably 
heterogeneous. Their distinctive subsets have been defined across different tissues 
(Guilliams et al., 2016b; Schlitzer and Ginhoux, 2013). Selective expression of antigen-
sensing TLRs and pattern-recognition receptors (PRRs) (Merad et al., 2013) allows 
DCs to instruct tailored responses (inflammatory or tolerogenic) to particular 
pathogens, vaccines, tumors or self-antigens by the induction of specialized T helper 
cell subsets (Everts et al., 2016; Idoyaga et al., 2013; King et al., 2010; Schlitzer et al., 
2013b; Tussiwand et al., 2015). Given the specialized and potent function of DCs to 
initiate or dampen adaptive immune responses, their presence in the CNS is highly 
relevant in the maintenance of a quiescent immune environment within the CNS and 
also in the context of initiating neuroinflammatory diseases. 
Early studies that localized BAMs in rat tissue by rudimentary histology also found rare 
OX6+ (rat MHCII equivalent), OX62+ (rat CD11c equivalent) cells they called DCs 
within dura mater, leptomeninges and choroid plexus (McMenamin, 1999). Later 
histology stainings showed the presence of CD209+ (DC-SIGN) DCs in the meninges 
of healthy human brains and not in the parenchyma (Serafini et al., 2006). Meningeal 
and choroid plexus DCs were then shown to have a life span of 5-7 days, and to be 
dependent on bone marrow progenitors and the FMS-like receptor tyrosine kinase 3 
ligand (Flt3L) (Anandasabapathy et al., 2011) which is a hematopoetin required for the 
maintenance of peripheral DCs (Kingston et al., 2009; Waskow et al., 2008). 
The functional relevance of CNS DCs as APCs was tested by co-culture experiments 
with sorted CD11c+ meningeal DCs and T cells and found to potently activate T cell 
proliferation in vitro (Kivisäkk et al., 2009). During neuroinflammation, DCs are 
known to accumulate within the CNS. Early studies showed that DCs accumulate in 
the CNS perivascular space and adjacent parenchyma during neuroinflammation in the 
rat (Matyszak and Perry, 1996b). During Multiple Sclerosis (MS), CD209+ DCs were 
shown to accumulate in the meninges and in perivascular spaces near MS lesions in 
close proximity to T and B cells, and also within the parenchyma (Serafini et al., 2006). 
A pivotal study demonstrated in experimental autoimmune encephalomyelitis (EAE), 
the mouse model for MS, that Flt3L-dependent CD11c+MHCII+ DCs were in fact 
sufficient and required for the reactivation of primed T cells and for the subsequent 
CNS invasion of peripheral leukocytes and progression of EAE (Greter et al., 2005). 
Indeed, MHCII+ cells were shown ex vivo to interact with CD4+ T cells in the 
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subarachnoid space during EAE (Kivisäkk et al., 2009). While these cumulative results 
show that CNS DCs are present in the steady state CNS and likely critical during 
neuroinflammation, these studies fall short of definitively assigning a non-redundant 
and essential role for DCs as the APCs at CNS borders during neuroinflammation. The 
reason for this is one of APC identity: Once again, a clear distinction between DCs and 
BAMs, BAMs being plastic cells that can upregulate CD11c during inflammation and 
can also express MHCII, as well as the distinction between DCs and monocyte-derived 
cells (MdCs) which invade the meninges, perivascular spaces and parenchyma during 
EAE and MS and also express CD11c and MHCII, was not established in these 
experiments. The relevance of properly identifying the CNS APC required for initiation 
of neuroinflammation is that DCs, BAMs and MdCs have different ontogenies, life 
spans, timed appearance in the CNS during inflammation, and may well have beneficial 
or detrimental functions during CNS diseases like MS. Therefore, therapies must be 
able to specifically target the right cell type. 
 
 
1.4. The role of the immune system in brain pathologies 
Since microglia are in direct contact with parenchymal neurons of the brain and spinal 
cord and other immune cells are considered to be excluded from the parenchyma in 
normal conditions, the role of microglia in brain pathologies has been studied 
extensively. Genetic associations and functional evidence implicates microglia in the 
pathogenesis of neurodegenerative diseases. However, whether the role of microglia is 
neurotoxic or neuroprotective may depend on the type of neurological disease and the 
timing during disease progression. The tilt toward harmful or beneficial outcomes is a 
highly regulated process and depends on the activating conditions and likely the cell-
intrinsic age. Microglia express a wide range of sensing receptors (Hickman et al., 
2013) and in response to different signals can change their morphology from a ramified 
to a spherical shape and move to sites of damage. Signals can be constitutively derived 
from normal neurons to maintain a calming, homeostatic state in microglia, or derived 
from infection, damaged cells or trauma and induce a range of reactive microglial states 
(phagocytic, pro-inflammatory) which can later progress to a more repairing state with 
elimination of the activating signals (Figure III). 
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Figure III. 
Microglial 
activity states 
are plastic and 
signal 
dependent. 
Microglial cells 
in the surveillance (sentry) state—traditionally termed 'resting' state—constantly scan for 
signals that would indicate a potential threat to CNS homeostasis. The appearance of such 
'activating' signals (in infection, trauma, cell impairment, hyperactive neurons) or the loss of 
constitutive 'calming' signals triggers a transition to an alerted state. Signals and their context 
are interpreted and converted to an initial response of 'activation'. Cells hence further commit 
to distinct reactive phenotypes, constituted by transcriptional profiles and phenotypic changes, 
and enter their executive phase (for example, release of cytokines and chemokines, phagocytic 
activity of damaged neurons and debris). Three examples are depicted (phenotypes 1, 2, 3), but 
the diversity could be larger. Throughout the subsequent period, the reactive behavior of 
microglia may change (reactive phenotypes 2.1, 3.1), largely controlled by a fading (or 
elimination) of the initial activating signals as well as influences from astrocytes and neurons, 
or invading immune cells (illustrated as feedback signals, grey arrows). Reactive phenotypes 
may thus shift, eventually leading to a more repair-orientated profile. While some cells may die 
(indicated by an 'X' over cell), others may revert to a 'resting' (surveying) state. Some cells may 
not retransform to a completely naive status and may remain as 'post-activated' microglia. These 
cells could keep subtle changes, for example, in transcriptional activity, that affect their 
sensitivity to constitutive (calming) signals or alter responses to subsequent stimulation. Post-
activated microglia could thus have acquired some experience (indicated as memory in the 
figure by a floppy disk icon). Figure and legend adapted from (Hanisch and Kettenmann, 2007).  
LymphocyteReactive microgliaResting microglia
Astrocyte Neuron Damaged neuron
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1.4.1. Neurodegenerative diseases and dementia 
1.4.1.1 The aging brain 
During aging, chronic inflammation in the body gradually and increases, a process 
termed “inflammaging”. On the other hand, immune response to infection gradually 
becomes less potent due to immune-senescence (Deleidi et al., 2015). The effects of 
aging on microglia are conceivably 2-fold: microglia may react to aging-related 
changes in their environment, and microglia may be directly affected by the aging 
process. In the aging brain, microglia change morphology from a highly ramified 
“resting” cell to a “dystrophic” cell characterized by de-ramification, the presence of 
shortened tortuous processes, and/or cytoplasmic fragmentation (Streit et al., 2004). 
The cause of the dystrophic state of microglia in aging may be due to chronic systemic 
inflammaging and senescence. However, it is consistently reported that the total 
number and density of microglia increases with age in various brain regions (Reu et al., 
2017). Therefore, dystrophic microglia may not be senescent in their potential to 
replicate and may resemble activated microglia. The hallmarks of microglial aging may 
also sometimes be characterized as dysfunctional and even hyper-reactive responses. 
Myelin debris has been demonstrated to accumulate in aging microglia, in which it 
forms insoluble, lipofuscin-like lysosomal inclusions and likely contributes to their 
increased density (Safaiyan et al., 2016). Population-based autopsy studies of the brains 
of aged people who had not been diagnosed with a neurological disease consistently 
report the presence of protein aggregates like amyloid plaques, neurofibrillary tangles, 
Lewy bodies, inclusions of TAR DNA-binding protein 43, as well as synaptic 
dystrophy, the loss of neurons and the loss of brain volume in most of the brains 
(Elobeid et al., 2016). It is unknown what causes such lesions and whether they are the 
precursors to neurodegeneration and disease or simply the products of brain aging and 
microglial dystrophy (Figure IV) (Wyss-Coray, 2016). 
 
1.4.1.2. Alzheimer’s disease 
Over 46 million people worldwide live with dementia today. Late onset AD is the most 
common cause of dementia in the elderly. The processes that characterize AD  
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Figure IV. Aging and neurodegeneration. As the brain ages, abnormal protein assemblies 
and inclusion bodies take hold and abnormal lysosomes are observed more frequently. It is 
unclear whether these defects promote aging and neurodegeneration or whether they are 
innocent bystanders. Aged brains become highly prone to neurodegenerative diseases in which 
the same lesions amass as those that are found in old brains in smaller numbers. The relationship 
between such lesions and cognitive impairment is often blurred and normal aging and 
neurodegeneration and dementia can overlap. Figure adapted from (Wyss-Coray, 2016). 
 
 
take place in most old brains; however, some people might have compensatory 
mechanisms that enable them to cope with these processes and to maintain normal 
cognition. Accordingly, it may be that AD phenotypes represent an exaggerated state 
of microglia dysfunction beyond that observed during normal aging (Wyss-Coray, 
2016). 
AD pathology is distinguished by the presence of both amyloid plaques and 
neurofibrillary tangles (NFTs). Extracellular plaques deposited in the brain parenchyma 
consist predominantly of Ab peptides derived from the amyloid precursor protein 
(APP), which is an integral membrane protein expressed in many tissues and 
concentrated in the synapses of neurons in the brain. NFTs consist of intracellular 
deposits of aggregated, hyper-phosphorylated tau protein within neurons. Ab plaques 
begin to form in the brain about 15–25 years prior to the onset of cognitive decline or 
the development of tau pathology (Ulrich et al., 2017), and can disrupt synaptic 
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transmission, induce oxidative stress and trigger cell death in vitro (Benilova et al., 
2012). 
The link between AD and the immune system gained a lot of interest when Genome-
Wide Association Studies (GWAS) demonstrated strong genetic implications for 
microglial molecules and the immune system in general with AD. Most prominent was 
the identification of the R47H loss-of-function mutation in TREM2 (“triggering 
receptor expressed on myeloid cells 2”) as a major risk factor for AD (Guerreiro et al., 
2013; Jonsson et al., 2013). TREM2 is an innate immune receptor expressed exclusively 
by microglia within the parenchyma and thus provided the clearest link between 
microglial dysfunction and AD pathogenesis. However, whether this link is causal is 
still unclear, and whether microglia act as a friend or a foe in AD may depend on the 
time point during the disease progression and the location within the brain. 
In a mouse model for AD, Ab plaques formed rapidly within 24 hours and subsequently 
recruited activated microglia to the plaques within 1–2 days (Meyer-Luehmann et al., 
2008). This dispelled previous notions that microglia may actually contribute to plaque 
formation. Microglia are activated by Ab via various pathogen- or danger-associated 
molecular patterns (PAMPs, DAMPs) within the microglial sensome, including TRL-
4 and its co-receptor CD14 (Lucin and Wyss-Coray, 2009; Reed-Geaghan et al., 2009). 
Microglia phagocytose Ab well in vitro, however there was no clear consensus in vivo 
as to whether microglia possess the capacity to clear Ab. When microglia were depleted 
from the brains of adult AD mice, there was no effect on Ab dynamics, suggesting that 
aged microglia may not be actively phagocytosing and clearing plaques in the AD brain 
(Grathwohl et al., 2009). The only time that microglia were able to reduce plaque load 
was after adult microglia were depleted and replaced with juvenile microglia in 
organotypic hippocampal slice cultures (Hellwig et al., 2015). Perivascular 
macrophages and infiltrating monocyte derived macrophages take up and degrade Ab 
more efficiently than adult microglia (Hawkes and McLaurin, 2009; Majumdar et al., 
2008). However, parabiosis experiments showed that when wild-type mice are joined 
with GFP mice, GFP monocytes do not enter the brain under normal conditions or after 
CNS insult (Ajami et al., 2007). 
While microglia may only play a minor role in amyloid clearance in vivo, they may 
contribute to secondary neurodegeneration via release of neurotoxic factors. However, 
recent studies have pointed towards a neuroprotective role for microglia during AD, 
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demonstrating that microglia act like garbage compactors, tightly surrounding Ab 
plaques and making them less damaging to surrounding neurons (Condello et al., 2015). 
This barrier formation was abrogated in TREM2-/- AD mice (Yuan et al., 2016). While 
only about 0.5% of AD patients actually have a loss-of-function TREM2 mutation, 
defective microglial barrier function may arise due to dystrophic senescence of 
microglia with age (Condello et al., 2017). 
 
 
1.4.2. Neuroinflammation 
While the cause of neurodegeneration in dementia and AD is still unclear, 
neuroinflammatory diseases are a direct result of strong inflammation within the CNS, 
either against a foreign pathogen or in an autoimmune reaction. In aging and AD there 
are subtle changes in microglial morphology, while in neuroinflammatory disease the 
entire immune landscape changes dramatically. CNS-resident immune cells become 
activated and the entire CNS is infiltrated by inflammatory leukocytes from the 
periphery (Galea et al., 2007). Microglia, DCs and BAMs, together are likely to be key 
to these processes, whether during initiation or propagation of neuroinflammation. 
 
1.4.2.1. Multiple sclerosis 
MS is one of today’s most prevalent autoimmune diseases, affecting almost 10’000 
patients in Switzerland (Pugliatti et al., 2006) and about 2.5 million worldwide. MS is 
a chronic inflammatory disorder of the CNS, i.e. the spinal cord and brain, resulting in 
demyelination, axonal degeneration and disability. The pathological hallmark of MS is 
lesions or plaques found in the white and grey matter of the CNS. Infiltrating 
inflammatory leukocytes cause demyelination and loss of oligodendrocytes (neuroglial 
cells which normally insulate axons and produce myelin) at these MS lesions (Dendrou 
et al., 2015). MS presents with a heterogeneous set of clinical features. Frequently 
observed signs are cognitive impairments like attention deficits, fatigue, visual 
disturbances such as reduced color vision and acuity as well as affection of motor 
functions manifesting as poor balance, limb incoordination or spasms (Compston and 
Coles, 2008). 
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EAE is currently the best model used to study MS and while it is an artificially induced 
autoimmune disease and does not capture fully the complexity of MS progression, it is 
still the gold standard (Schreiner et al., 2009). During EAE and likely MS as well, 
infiltration starts in the meninges and proceeds deeper into the parenchyma (Kivisäkk 
et al., 2009). While meningeal infiltration is antigen independent, parenchymal 
infiltration is antigen dependent (Lodygin et al., 2013) and has already been discussed 
in this thesis. During EAE, infiltrating auto-reactive T cells recruit inflammatory 
monocytes through production of the cytokine GM-CSF (Croxford et al., 2015b). 
Inflammatory monocytes differentiate into MdCs which may be a mixture of monocyte-
derived DCs and macrophages, and it is MdCs which are thought to cause the 
destructive demyelination (Spath et al., 2017; Yamasaki et al., 2014). 
As in aging and AD, the role of microglia during EAE and MS is still unclear. Microglia 
lose their homeostatic morphology in MS lesions (Zrzavy et al., 2017). For many years 
the distinction between MdCs and activated microglia in the inflammatory setting of 
EAE and MS has been challenging as their morphological and phenotypic features 
become merged due to activation within the inflammatory environment. Again, use of 
irradiation methods to deplete and transplant traceable bone-marrow derived cells and 
study radiation-resistance microglia proved misleading due to the artificial disruption 
of the BBB and contribution of monocyte-derived microglia to the microglial pool 
(Ajami et al., 2007). However, using genetic reporters to discriminate these cells and 
high-resolution imaging techniques, microglia were shown to be have myelin 
inclusions but were relatively inert during onset of EAE (Yamasaki et al., 2014). 
Despite the technical drawbacks, most data point to a generally detrimental role of 
microglia in EAE and MS. Expression of the co-stimulatory molecule CD40 (Becher 
et al., 2001) or the cytokine IL-23-p40 (Becher et al., 2003) by microglia worsened 
EAE symptoms. Paralysis of microglia through genetic activation of the toxic 
ganciclovir derivative also worsened EAE symptoms (Heppner et al., 2005). Microglia 
may contribute to neurodegeneration during MS as the “calming” regulatory molecules 
CD200 and CD47 (“don’t eat me signal”) normally expressed by neurons are down-
regulated within the center of chronic active MS lesions as well as the surrounding 
normal-appearing white matter (Koning et al., 2007).  
Importantly, our current knowledge about how CNS-resident immune cells react during 
CNS pathologies has depended largely on ambiguous morphological changes and a few 
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select protein markers. Better tools and cell type-specific markers are required to clearly 
distinguish these cells from each other and from infiltrating inflammatory cells, and to 
compare the range of responses they have under different pathological conditions. 
 
 
1.5. High parameter cytometry techniques 
1.5.1. Fluorescence-based cytometry 
Fluorescence-based cytometry (or flow cytometry) is a critical technique in the study 
of the immune system. A flow cytometer counts different types of cells in a liquid 
suspension that are passed rapidly in a stream within the flow cell, by their expression 
of specific surface or intracellular markers (receptors, cytokines, nucleic acids, genetic 
reporter proteins). The detection of these markers on cells is enabled by their labeling 
with antibodies that have been conjugated with unique fluorescent dyes (fluorophores 
or colors), and a series of lasers and photonic detectors within the cytometer. Since its 
inception in 1965 (Fulwyler, 1965) and its first use in the 1970s (Gray et al., 1975), the 
basic design of a flow cytometer has remained almost unchanged, highlighting the 
robust design of the technology (Robinson and Roederer, 2015). The epidemics of 
HIV/AIDS in the 1980s gave a dramatic impulse to flow cytometry, since it became 
clear that the quantification of the number of peripheral blood CD4+ T cells was crucial 
to follow the course of the infection, and eventually for monitoring the therapy 
(Cossarizza et al., 2017). Since then, flow cytometry has established itself as the 
workhorse for high-throughput quantitative analysis of cells and other particles. Other 
aspects contributing to the success of flow cytometry include the speed at which cells 
are analyzed (allowing large numbers of cells to be measured), the high accuracy and 
resolution and the low operating costs per sample. Importantly, flow cytometry is 
regarded as a non-destructive technology, being able to viably sort cell populations for 
further subsequent analyses. 
Flow cytometry also has some considerable limitations. While 18-color flow cytometry 
is now routinely used in labs, the immune system is far more complex than the number 
of individual fluorochromes available and our ability to detect and resolve them with 
respect to the overlap between their induvial emission spectra (a phenomenon termed 
spectral overlap). The number of commercially available fluorochromes has steadily 
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risen over the years. The optical setup (including laser, detector and filter 
configurations) able to detect them within the cytometer has recently advanced with the 
emergence of the Becton Dickinson FACSymphony flow cytometer which technically 
allows the measurement of up to 50 parameters. In practice, however, this high is 
number not achievable because at the moment the range of appropriate fluorescent dyes 
is limited. 
 
1.5.2. Mass cytometry 
1.5.2.1. The principle of mass cytometry 
An alternative cytometry based technique has been developed that relies on antibodies 
labeled with non-radioactive heavy-metal isotopes instead of fluorophores, detecting 
the resulting signals using a time-of-flight  (TOF) mass spectrometry detector (Bandura 
et al., 2009; Bendall et al., 2012; Ornatsky et al., 2010; Tanner et al., 2013). This method 
has been termed “mass cytometry” and became commercially known as the “CyTOF” 
(cytometry by time-of-flight), allowing the theoretical detection of more than 100 
parameters per cell (Bendall et al., 2012; Tanner et al., 2013). Practically however, the 
limit is currently somewhere near 50, due to availability of isotopically pure metals. 
The technological advance of the metal-tagged antibody detection by TOF in CyTOF 
over the fluorescence-tagged antibody detection by optical detectors in flow cytometry 
is a giant leap in the field and is based on the circumvention of spectral overlap 
phenomenon with the use and detection of unique metal isotopes discretely separated 
by one atomic mass unit (amu) and having less than 1 part in 106 overlap (0.0001 %) in 
the adjacent mass channels (Tanner et al., 2013) (Figure V).  
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Figure V. Fluorophore emission and heavy-metal isotope spectra used in flow and mass 
cytometry, respectively. An eight-parameter flow cytometry experiment illustrating the 
spectral overlap between the fluorophores. Mass cytometry involves the collection of mass 
spectral data in distinct isotope channels with 1 atomic mass unit space between each channel. 
(Virani & Tanner, 2015) 
 
 
The workflow and acquisition process in CyTOF is described in Figure VI. Cell 
suspensions stained with heavy-metal isotope tagged antibodies are injected into the 
mass cytometer where they reach a nebulizer which creates single-cell droplets from 
the cell suspension. These droplets are introduced into an inductively coupled plasma 
(ICP) (Houk et al., 1980). This ICP is high-temperature (7000°K at the surface to 
55’000°K at the core), supported by a flowing argon stream, and vaporizes, atomizes 
and subsequently ionizes the cells (Tanner et al., 2013). The resulting ion cloud if then 
filtered through a quadrupole which allows only heavy-metal ions (which are not 
normally found in cells) to pass but blocks the low mass ions of biological elements 
commonly found in cells. Lastly, the ion cloud is divided into pushes and the metal 
isotopes are quantified by the TOF mass analyzer. The data is stored in the flow 
cytometry standard (*.fcs) file format which is compatible with standard flow 
cytometry data analysis software (like FlowJo). 
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Figure VI. Schematic of ICP-mass spectrometry-based analysis of cellular markers. An 
antibody tagged with a specific mass isotope binds to the cellular epitope on the cell. The cell 
is introduced into the ICP by droplet nebulization. Each cell is atomized, ionized, overly 
abundant ions removed, and the elemental composition of remaining heavy elements (reporters) 
is determined. Signals corresponding to each elemental tag are then correlated with the presence 
of the respective marker and analyzed using conventional cytometry platforms. (Bendall et al., 
2012) 
 
 
1.5.2.2. Antibody conjugation with metal tags 
An important part of CyTOF technology is the conjugation of antibodies with heavy-
metal isotope tags. This is achieved by complexing the desired metal isotopes, as ions 
from a salt solution, into metal chelating polymers which are then covalently bound to 
the antibodies or directly to proteins within fixed and permeabilized cells. The 
elemental metals used have low natural abundance, thus exhibiting a very low 
background signal during acquisition. The range of elemental metals currently available 
in high enough purity and used in mass cytometry as shown in Figure VII. The mass 
range of the detector is currently 75 – 209 amu. The focus for panel antibody labeling 
is on the lanthanide (Ln) series of elements because of the large number of stable 
resolvable isotopes having similar chemistry that facilitates their incorporation into the 
same chelating polymer structure, as well as the peak of detector sensitivity within that 
mass range. Platinum (Pt) can be used to discriminate dead cells as it binds non-
specifically to exposed proteins within membrane-compromised (dead) cells (Fienberg 
et al., 2012). Iridium (Ir) and rhodium (Rh) can be used as a cell ID markers (important 
	20	
since there is no forward and side scatter) as they intercalate with DNA (Ornatsky et 
al., 2008). Palladium (Pd) can be used for mass-cell barcoding (MCB) of samples which 
allows for the pooling of samples (Zunder et al., 2015a). Staining and acquiring pooled 
samples prevents inter-staining variability and normalizes the signal drift that occurs 
during acquisition, respectively.  
By attaching 3 to 4 polymers to one antibody, about 100 metal ions can be coupled to 
a single antibody (Ornatsky et al., 2010). Polymers are purchased attached to a linker 
that binds either reduced sulfide (-SH) groups on the Fc portion of the antibody or to 
amine groups within the cell. The choice of chelator depends on the binding affinity for 
the metal ion as well as its binding to regions of the antibody. Prominent polymer 
chelators at the moment are based on DTPA (diethylene triamine pentaacetic acid) 
(Majonis et al., 2010), a version of which forms the commercial MaxPar X8 polymer, 
and DOTA (1,4,7,10-tetraazacyclodode-cane-1,4,7,10-tetraacetic acid) (Lou et al., 
2007), which are usually attached to a thiol-reactive maleimade linker. These polymers 
form high affinity complexes with Ln3+ ions. Partial reduction of antibodies results in 
breaking disulfide bonds on the Fc portion of antibodies, exposing -SH groups which 
then bind the linker on the metal loaded chelator. Full reduction of the  
 
Figure VII. Heavy-metal isotopes currently available for mass cytometry. The stable 
isotopes of these 24 elements provide over 50 unique tags for use in mass cytometry. Sn (tin) 
has also shown promise for use in mass-tag cell barcoding with 10 available pure isotopes 
(personal correspondence with Christoph Schwärzler). Figure taken from Fluidigm. 
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antibody is undesirable as it would also expose -SH groups within the antigen-binding 
region of the antibody, thus disrupting its immune specificity.  
ETDA-based chelators are better suited to Pd2+ ions (Majonis et al., 2011) and when 
linked to ITCB (isothiocyanobenzyl, also called p-SCN) (Zunder et al., 2015a) can 
directly bind to amine-reactive groups within the cytoplasm of fixed and permeabilized 
cells and is therefore useful for MCB. ITCB-EDTA-Pd has also be used to bind the 
human CD45 antibody for live cell barcoding (Mei et al., 2015), however, in our hands 
this did not work for mouse CD45. Other strategies are possible, including different 
combinations of metal-chelator-linker or even direct antibody labeling with metal, for 
example the use of platinum to directly label partially reduced antibodies (Mei et al., 
2016) or the use of free metal salts like palladium or tin (Sn) to directly stain fixed or 
live cells (personal observations and correspondence with Christoph Schwärzler). Thus, 
there are currently great efforts being put into optimizing the metal conjugation 
procedure for various antibodies, metals and mass-cell barcoding strategies for fixed 
and live cells. 
 
 
1.6. Algorithm-guided analysis of high parameter cytometry data 
1.6.1. Limitations of manual data analysis 
While both fluorescence-based flow cytometry as well as mass cytometry provide a 
technological platform to interrogate the immune system at a previously unprecedented 
level, scientific progress depends on our ability to analyze and comprehend the 
resulting data in a meaningful way. Historically, flow cytometric data was and still is 
being analyzed using a series of two-dimensional plots and manual “gating”, i.e. 
drawing regions of interest (gates) on a plot and either examining that subset on a 
different bivariate plot or reporting a certain qualitative measure (cell subset is present 
or absent, or its relative proportion) or quantitative measure (signal intensity in a 
particular channel). While this approach is still adequate for many experimental 
settings, it suffers from several serious shortcomings. First, it is not easily scalable, as 
the number of two-dimensional plots increases exponentially with the number of 
measured parameters (i.e. an 18-parameter experiment would require a total of 153 two-
dimensional plots to display every marker combination) and thus cannot be easily 
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comprehended anymore. Second, it has been shown by many multi-center studies such 
as the Human Immune Genome Project that manual gating is one of the largest variables 
in the outcome of a flow cytometry based experiment, and is thus not easily 
reproducible (Maecker et al., 2012). Third, every manual gating approach relies on prior 
knowledge of the researcher, thus introducing a bias towards “expected" results. Due 
to this focus, much of the potentially relevant and novel information within the dataset 
might not be recognized and end up being ignored. 
 
1.6.2. Dimensionality reduction – visualizing a similarity landscape 
A powerful tool to visualize multi-parameter cytometry data is nonlinear 
dimensionality reduction via t-stochastic neighbor embedding (t-SNE) (Amir et al., 
2013; Van Der Maaten and Hinton, 2008). The difference between t-SNE and the 
commonly used dimensionality reduction algorithm, principle component analysis 
(PCA), is that PCA assumes linear relationships between the measured parameters, 
meaning that co-expression or co-variance of molecules is linearly correlated with 
important progressions in cellular identity or trajectories in data space. However, this 
is not the case for many biological datasets (Diggins et al., 2015). t-SNE visualizes 
high-dimensional similarities of cells in an easily understandable two- or three-
dimensional scatter plot, the so-called t-SNE map. The proximity of cells in the t-SNE 
map reflects their distances in the high-dimensional space. Cells that are similar in their 
analyzed protein-expression pattern will be located closely together in the t-SNE map, 
thus enabling the visualization of different cellular subpopulations. However, this is 
only true to a certain extent: the more dissimilar the cells are, the less proportional to 
their dissimilarity the distance between them becomes. This is to prevent overcrowding 
of the center of the t-SNE map and preserves the local structure of the data while 
potentially exaggerating global structure (i.e. some different cells may appear to be 
more different than they really are) (Van Der Maaten and Hinton, 2008). Importantly, 
t-SNE has been shown to successfully identify small immune subpopulations (Amir et 
al., 2013) and is able to recognize high-dimensional associations of markers which 
might be missed when performing conventional, two-dimensional gating (Figure VIII). 
Briefly, the computational steps underlying t-SNE are first the calculation of a pairwise 
similarity matrix for all data-points, based on their high-dimensional distances. Next, a 
	23	
low-dimensionality similarity matrix is calculated based on initially random locations 
for each cell in the two (or three) t-SNE dimensions. In an iterative process, the 
algorithm then tries to minimize the difference between the high- and low-dimensional 
similarity matrices, thereby adjusting every cell´s position in the two-dimensional space 
(Van Der Maaten and Hinton, 2008). Recent improvements make use of the Barnes-
Hut algorithm (van der Maaten, 2013) which uses a tree-like structure to reduce the 
number of pairwise similarities that actually have to be calculated. This now allows for 
a higher number of cells to be analyzed and shorter computation time. On the resulting 
t-SNE map, different immune subpopulations might visually appear as distinct clusters, 
however t-SNE does not per se assign single cells to defined clusters. This can be 
accomplished either by subsequent manual gating on the t-SNE map or by using 
automated clustering algorithms (Figure VIII, b).  
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Figure VIII. viSNE map of healthy human bone marrow. (a) In a synthetic toy example, 
(1,000 points randomly distributed with normally distributed noise around a polynomial of the 
third degree) viSNE projects a one-dimensional curve embedded in three dimensions (left) onto 
two dimensions (right). The color gradient shows that points that are in close proximity in three 
dimensions remain in close proximity in two dimensions. (b) Application of viSNE to a healthy 
human bone marrow sample, stained with 13 markers and measured by mass cytometry, 
automatically separates cells into spatially distinct subsets based on the combination of markers 
that they express. Each point in the viSNE map represents an individual cell and its color 
represents its immune cell subset as designated by independent expert manual gating (manual 
gates are defined at the bottom). Gray points were not classified by manual gating. The axes 
are in arbitrary units. (c) Biaxial plots represent the same data shown in b, and show the gates 
drawn manually by expert operators. The colors of the squares match the colors in b. The actual 
manual gating used here is more complex and uses a series of biaxial plots to gate each 
population. Note, that unlike in b, no single biaxial plot spatially separates all subsets. (d) The 
same viSNE map shown in b is colored according to intensity of CD11b expression. Many of 
the cells within the dotted line gate were not classified as monocytes by manual gating (gray 
cells, b). Figure and legend taken from (Amir et al., 2013). 
 
 
1.6.3. Environments for cytometry data analysis 
Various implementations of t-SNE exist. viSNE is the implementation developed in 
Dana Pe’ers' lab and distributed as a part of CYT, an interactive visualization tool based 
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on MATLAB that is free for academic use and contains a graphical user interface (Amir 
et al., 2013). Cytobank, an online platform for cytometry analysis, has viSNE as an 
integrated tool among other tools. t-SNE has also been directly implemented in various 
programming languages (R, Python, C++, Matlab) which are freely available for 
download. R is highly suited to cytometry data analysis and, within R Studio, has a 
graphical interface for visualizing plot outputs. Bioconductor (www.bioconductor.org) 
(Gentleman et al., 2004) is an open source repository that contains packages for R that 
deal with various aspects of cytometry data handling. Additionally, Github 
(www.github.com) contains software published by developers with instructions for 
implementation in R (or other languages). 
 
1.6.4. Clustering – defining borders in the similarity landscape 
Clustering algorithms directly assign cells to distinct clusters which can then be 
overlaid onto a t-SNE map or minimum spanning tree (or onto any other plots that 
visualize the cells). There are many different clustering algorithms which vary in the 
way that they calculate similarity between cells which can translate to efficiency at 
finding rare populations and in the duration of the runtime. For a comprehensive 
comparison, see (Saeys et al., 2016; Weber and Robinson, 2016). 
 
1.6.4.1. SPADE 
SPADE (Spanning-tree Progression Analysis of Density-normalized Events) (Qiu et 
al., 2011) was one of the first algorithms to be used in immunology publications. 
SPADE depicts cell populations in a branched tree structure and consists of connected 
nodes that represent clusters of cells, thereby also providing information about the 
relationship between cell types. SPADE includes a density-dependent down-sampling 
(ensuring inclusion of rare cell types with few similar neighbors) followed by 
hierarchical, agglomerative clustering (grouping cells into a user-defined number of 
clusters), construction of a minimum spanning tree (MST) with edges connecting the 
nodes, iterations to connect all nodes to the tree and lastly, for all cells in the initial 
dataset SPADE determines the closest neighbor in the down-sampled data and assigns 
the cell to the corresponding cluster. Since SPADE includes steps involving random 
decisions, it is of a nondeterministic nature. As a consequence, several runs of SPADE 
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will result in differently organized trees.  
 
1.6.4.2. FlowSOM 
In this thesis, we made use of the FlowSOM algorithm (flow cytometry data analysis 
using self- organizing maps) (Van Gassen et al., 2015) as it defines population clusters 
efficiently and with the fewest mismatches, and is computationally light and fast 
compared to other algorithms (Weber and Robinson, 2016). FlowSOM is based on the 
principle of self-organizing maps (SOMs) which is an unsupervised technique for 
clustering and dimensionality reduction (Kohonen, 1990). The workflow is outlined in 
Figure IX. After optional preprocessing steps, a SOM is built from the input data 
without sub-sampling. SOMs are a type of artificial neural network, consisting of a grid 
of 100 nodes, in which each node represents a point in the original multi-dimensional 
input space. New points are added and classified with the node that is the closest 
neighbor. The grid is trained in such a way that nearby nodes resemble each other more 
than nodes that are further away by repeatedly picking a point from the dataset, finding 
the node nearest to it and updating all the nodes in the neighborhood of that node. As 
the next step, the SOM is visualized as a MST (similar to SPADE). Lastly, a 
metaclustering step is performed, employing consensus hierarchical clustering where 
the number of metaclusters is determined by the user-defined k-value. 
 
1.6.4.3. PhenoGraph 
PhenoGraph (Levine et al., 2015) models the high-dimensional space using a k-NNG 
(k Nearest Neighbor Graph), in which each cell is depicted as a node that is connected 
to its neighbors by edges. In this graph, phenotypically similar clusters of cells will be 
represented as sets of highly interconnected nodes. These can be seen as 
“neighborhoods” or “communities” of cells, and can be partitioned in high-dimensional 
space using similar community-detection algorithms used for the analysis of social 
networks. While PhenoGraph performs well, its runtimes are up to 10 times longer than 
FlowSOM.  
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Figure IX. Overview of the four steps of the FlowSOM algorithm. (i) The fcs-files are read, 
optionally compensated, transformed, concatenated and scaled, resulting in a matrix with a row 
for every cell, describing the measured marker values. (ii) A self-organizing map is trained on 
the matrix. The result is a grid of nodes, corresponding to cell clusters. Visualizations can be 
made showing the mean marker values of each node in star charts (a) or the concordance with 
a manual gating in pie charts (b). (iii) A minimal spanning tree is built, on which the same 
information can be visualized (c,d). We can also show mean marker values for specifically 
chosen markers, resulting in figures very similar to SPADE trees (e). (iv) A meta-clustering of 
the nodes is calculated, corresponding to an automatic gating procedure. This is indicated by 
the background color of the nodes, and can be both visualized in the grid (f) or the minimal 
spanning tree (g). Figure and legend adapted from (Van Gassen et al. 2015). 
 
 
1.6.4.4. X-shift 
X-shift (Samusik et al., 2016) exists in a standalone Java application (VorteX clustering 
environment) with an easy-to-use graphical interface (the command-line version is also 
available). Very briefly, X-shift employs weighted k-NN density estimation, detection 
of local density maxima which form region centroids, connection of centroids via a 
graph, and cluster merging. The clusters can then be displayed on a variety of different 
visualizations within VorteX. Although X-shift runtimes are longer than FlowSOM 
runtimes, X-shift is the most successful algorithm to date at accurately finding rare 
populations (Weber and Robinson, 2016).  
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1.6.5. Force-directed graphs – measuring similarity and integrating data sets 
While t-SNE groups cells based on their similarity in the high-dimensional space, the 
distances between cells are less accurate the more dissimilar they are and therefore not 
necessarily directly proportional to their similarity (Van Der Maaten and Hinton, 2008). 
To accurately show the hidden structure within the data, the similarity distances can be 
represented by edges that are controlled by a force-directed graph algorithm (Jacomy 
et al., 2014; Spitzer et al., 2015). While SPADE visualizes cell clusters in a MST with 
nodes that are also interconnected by edges, the MST used by SPADE is susceptible to 
overfitting the data and is not robust to local variation (Zunder et al., 2015b). Force-
directed approaches are based on a set of “forces” that guide data organization. Nodes 
(in this case, groups of cells) that are similar are connected by edges with a length 
proportional to their similarity. These nodes are then spatialized into a graph: initially, 
all nodes repel one another as if they were the same poles of magnets, but edges pull 
similar nodes together, acting like springs.  
Scaffold (single-cell analysis by fixed force- and landmark-directed) maps use force-
directed graphs in combination with CLARA (clustering for large applications) 
clustering of the nodes (Spitzer et al., 2017; Spitzer et al., 2015). Scaffold also includes 
known manually gated populations as landmark nodes on the graph, around which 
unsupervised nodes are grouped, allowing for easier interpretation of the cell 
populations (Figure X). Landmark nodes are fixed in position to form a reference map. 
What makes Scaffold very useful is that it allows the mapping of independent datasets 
onto a reference map. For example, this can facilitate the integration of CyTOF and 
FACS data from different experiments, or the mapping of a systemic immune response 
in different organs compared to a reference map from the bone-marrow, for example. 
Furthermore, Statistical Scaffold (Spitzer et al., 2017) measures the changes between a 
reference map and an interrogated map and colors the nodes by statistical significance. 
The VorteX application also includes a single-cell force-directed graph layout for 
visualizing X-shift clustered data which can also be used as a reference map, allowing 
direct comparison of datasets (Samusik et al., 2016). A comparison of a Scaffold and 
X-shift map are shown in Figure XI. 
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Figure X. Schematic of the Scaffold map algorithm. (i) Bone marrow from C57BL/6 
mice was chosen as the reference sample. (ii) Leukocytes are grouped according to 
prior knowledge to define landmark cell populations as reference points on the map. 
The same leukocytes are subjected to unsupervised clustering with CLARA to provide 
an objective view of the tissue composition and organization. An example is provided 
using CD4+ and CD8+ T cells. (iii, iv) Both landmark populations (red nodes) and 
unsupervised clusters (blue nodes) are used to generate a force-directed graph in which 
similar nodes are located close together proportional to the similarity of their protein 
expression. Thus, similar nodes fall in proximity to one another while disparate nodes 
segregate apart from one another. Size of unsupervised clusters denotes the relative 
number of cells in that node. (v) Landmark populations from the bone marrow are fixed 
in place into a reference map for subsequent maps to provide points of reference for 
rapid human interpretation. (vi) Additional samples are each subjected to unsupervised 
clustering via the CLARA clustering algorithm. (vii) The resulting clusters for each 
sample were overlaid onto the original landmark nodes to generate tissue-specific 
Scaffold maps. Figure and legend adapted from (Spitzer et al., 2015). 
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Figure XI. A comparison between force-directed graph layouts. (left) A Scaffold 
map of C57BL/6 bone marrow showing landmark nodes (red) and nodes clustered by 
CLARA (blue) (Spitzer et al., 2015). (right) A single-cell force-directed graph of 
showing C57BL/6 bone marrow overlaid cells clustered with X-shift (color coded for 
48 clusters, k = 20) (Samusik et al., 2016). Panels used for staining the bone marrow 
differed. 
 
 
1.6.6. Other algorithms for modeling immunology systems 
One-SENSE (One-dimensional Soli-Expression by Nonlinear Stochastic Embedding) 
(Cheng et al., 2016), is a useful algorithm for displaying features of cells where 
measured parameters are grouped into predefined categories and each dimension (plot 
axis) has biological meaning that can be easily annotated with binned heat plots.  
A developmental trajectory can be modeled using Wanderlust (Amir, 2014; Bendall et 
al., 2014), and a branching trajectory using Wishbone (Setty et al., 2016). However, 
Wanderlust assumes an unbranching trajectory and Wishbone assumes a bifurcating 
one. If the presence of a branch within a progressive dataset is unknown, TreeTop 
(Macnair et al., 2017) can be used to test this hypothesis.  
The question following visualization and clustering of datasets usually involves finding 
the distinctive cell population that stratifies two sets of samples. Citrus provides an 
unsupervised and automated process that combines computational identification of 
cellular subpopulations with various association models to reveal stratifying clusters 
and cellular responses that are best predictive, or best correlated with the experimental 
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endpoint (Bruggner et al., 2014). CellCnn (Arvaniti and Claassen, 2017) performs a 
similar function to Citrus but is better suited to finding rare predictive cell types.  
Finally, once cell populations of interest within high-dimensional data sets have been 
identified, further functional experiments to determine their role in a particular context 
may be desired. In order to be able to isolate a cell type, markers that can identify it in 
low dimensions and are therefore suitable for FACS sorting are necessary. Marker 
Enrichment Modeling (MEM) (Diggins et al., 2017) can be used to extract the most 
distinguishing markers within the panel as it describes cells by quantifying contextual 
feature enrichment and reporting a human- and machine-readable text label. 
 
1.6.7. Practical considerations for automated data analysis 
The first practical aspect when starting to analyze high-dimensional data sets in an 
automated manner is to perform appropriate quality control (QC) and data pre-
processing. 
 
1.6.7.1. Data normalization and compensation for spillover 
While proper QC of both the instrument and acquired data should always be part of a 
standard cytometry analysis workflow, it becomes even more relevant with increasingly 
complex experiments. QC must include validation of the instrument used: and for 
fluorescence-based cytometry the assessment of signal stability over time as well as 
potential artifacts arising from improper compensation (reviewed in (Perfetto et al., 
2006)), and for mass cytometry the inclusion of EQ Four Element Beads with the 
sample during acquisition allows to the subsequent normalization of the data for the 
inevitable signal drift over long periods of acquisition time (Finck et al., 2013). 
Currently, compensation is not widely used for mass cytometry data as the spillover 
from certain channels is minor. This spillover is caused mainly by isotopic impurities 
in the metals used to label the antibodies, metal oxide formation (in the Mass (M) + 16 
channels) and mass cytometer properties (in the M ± 1 channels). However, recent 
attempts have begun to establish methods to correct for these artifacts (Chevrier et al., 
2017a). 
 
1.6.7.2. Data transformation 
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In addition to QC with respect to instrument and acquisition, automated analysis of 
high-dimensional data asks for dedicated pre-processing steps, especially data 
transformation. Epitope abundances measured by cytometry often follow normal 
distributions on a logarithmic scale (so called log-normal distribution) with the variance 
of different cell populations depending on their intensity. Therefore, obtaining a 
suitable representation of the data across its entire intensity range is crucial for 
visualization and particularly for automated analysis. To do so, different transformation 
methods can be employed (compared and reviewed in (Trotter, 2007) and (Finak et al., 
2010)). In the context of the aforementioned algorithms, the data is frequently 
transformed using either an inverse hyperbolic (arcsinh) or logicle transformation 
(Herzenberg et al., 2006; Parks et al., 2006). This leads to a suitable representation of 
the data for values around zero, as well as for values on the upper end of the range. 
Functions to perform such data transformations are commonly integrated into the 
respective analysis tools (R packages, CYT via Matlab, Cytobank). 
 
1.6.7.3. Percentile normalization 
Another pre-processing step, which can be employed in order to improve automated 
data analysis, is per channel percentile normalization of the data which normalizes for 
the varying staining intensities of different markers and allows for a uniform range of 
expression values (from 0 to 1). This makes heatmaps and expression values overlaid 
on t-SNE maps more readable and comparable between markers. 
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2. Aims of the study – mapping the CNS immune atlas 
The major aim of this study was to overcomes previous localization- and morphology-
dependent limitations in distinguishing different CNS-resident and -infiltrating immune 
cells and compared their range of reactive states during CNS pathology. For this 
purpose, we established highly multiplexed panels of protein surface markers for mass 
and flow cytometry. 
Our first aim was to fully characterize and map the steady state CNS immune landscape 
using mass cytometry and algorithm-guided data analysis. In order to be confident of 
our cell identification, we needed to validate our cell assignment. We aimed to do this 
through cell-specific response to different stimuli, the tracking of blood-derived 
leukocytes and labelling microglia and BAMs by genetic reporter and fate-map 
systems. We were particularly interested in new subsets of BAMs that we revealed 
through this analysis, and further aimed to localize them within specific compartments 
of the CNS by immunohistochemistry. Once our immune map of the steady state CNS 
was complete, our final aim was to interrogate the changes that occur during different 
forms of CNS pathology: aging and murine models of Alzheimer’s disease (APP/PS1) 
and Multiple Sclerosis (EAE), highlighting the similarities and differences between 
them. 
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3. Results 
3.1. CNS-Associated Immune Cell Populations in the Adult Steady State Mapped 
by Mass Cytometry 
We employed an integrated set of strategies to enable comprehensive mapping of the 
immune cell populations within the murine CNS, as shown in Figure 1A. To capture 
the full complexity of cellular phenotypes we designed a 43-heavy metal isotope-tagged 
surface antibody panel for mass cytometry (Table S1). Mass cytometry data was further 
complemented by 22-color fluorescence cytometry and the location of specific cell 
populations within the CNS was analyzed by IHC. 
We first interrogated the steady state CNS in 8-week-old C57BL/6 mice. To give an 
overview of all immune populations present, mass cytometry data was visualized in a 
t-SNE map and cells categorized by FlowSOM-guided clustering (Hartmann et al., 
2016) (Figure 1B, C and Figure S1A). This approach revealed an unprecedented 
complexity of leukocytes within the normal CNS: microglia and other macrophage-like 
cells, several types of monocytes (Ly6Chi and Ly6Clow monocytes, and MdCs), as well 
as classical DCs (cDCs), plasmacytoid DCs (pDCs), B cells (CD24+ and CD24-, see 
Figure S1A), T cells, NK cells, NK T cells, innate lymphoid cells (ILCs), eosinophils 
and mast cells. Manual gating of the mass cytometry data confirmed the identity of 
these cell populations (Figure S1B). Microglia 
(CD45lowCD11blowF4/80+CD64+MeTK+Cx3CR1hiSiglec-H+CD88low) were the most 
abundant immune cells in the steady state CNS (Figure 1D). Interestingly, we were able 
to identify a separate population of cells with a closely related protein expression 
pattern (CD45low/+CD11blowF4/80hiCD64hiMeTK+Cx3CR1+CD88hi); however, these 
cells were lacked typical microglial Siglec-H expression, and instead expressed CD206 
and CD38 (Figure 1C and S1A).  
Using IHC, Goldmann and colleagues recently described a population of embryonically 
derived macrophages with a microglia-like phenotype, but occupying distinct locations, 
namely the border regions of the CNS in contrast to the parenchyma where only 
microglia reside (Goldmann et al., 2016). We hypothesized that the non-microglia 
macrophage-like cells identified in our unbiased analysis were in fact BAMs. These 
BAMs are virtually indistinguishable from microglia using conventional 
(CD45/CD11b) gating strategies (Figure S1B).  
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Figure 1. Identification of CNS-Associated Leukocytes in the Steady-State by Mass 
Cytometry. (A) Schematic representation of the experimental approach. (B) t-SNE map 
displaying 100,000 randomly sampled cells from the CNS of steady-state 2-month-old 
C57BL/6 mice analyzed by mass cytometry. Colors correspond to FlowSOM-guided clustering 
of cell populations (n = 3, representative of 6 independent experiments). (C) Median marker 
expression values for each population. (D) Frequencies of steady-state CNS leukocytes. (E) 
Experimental schematic (left) and frequencies (right) of myeloid populations within total CNS 
leukocytes after indicated treatments (n = 3). See also Figure S1, S2 and Table S1. Error bars 
represent range. 
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To confirm this and the identities of the other cell populations present, we first used 
functional assays that exploit characteristic cell type-restricted responses to different 
stimuli. We treated mice with either an anti-CSF1R antibody to deplete tissue-resident 
macrophages and Ly6Clow monocytes, but not microglia (which are likely protected by 
the BBB) or Ly6Chi monocytes (Hoeffel et al., 2015), or with the growth factor Flt3L, 
which specifically expands DCs (Maraskovsky et al., 1996) (Anandasabapathy et al., 
2011). Indeed, anti-CSF1R treatment depleted the cells we identified as BAMs and 
Ly6Clow monocytes, but had no effect on other cell types (Figure 1E). The depletion of 
BAMs further confirms their location within the border regions of the CNS where the 
vasculature has different barrier properties to the BBB of the parenchymal vasculature 
(Engelhardt et al., 2017). Flt3L treatment in turn increased the frequency of DCs, as 
well as Ly6Chi monocytes and MdCs (after 9 days of treatment the bone-marrow 
monocyte progenitors are also targeted), while having no effect on microglial, BAM, 
or Ly6Clow monocyte populations (Figure 1E), thus functionally confirming our 
algorithm-guided population identification. 
To determine whether the leukocytes we detected in the CNS were within the tissue 
itself or within the lumen of vessels or capillaries, we intra-venously injected 
fluorescently (PE)-labeled anti-CD45 antibodies (Anderson et al., 2014). Over 98% of 
control blood leukocytes were labeled with anti-CD45-PE, while only 5% of CNS 
leukocytes were labeled (Figure S2A-C); thus 95% of all CNS leukocytes identified are 
bona fide extra-vascular CNS-resident cells. Neutrophils constituted the third largest 
leukocyte population in the CNS, 81.8 ± 3.0% being unlabeled and therefore tissue-
resident (Figure S2D and E). Tissue sections revealed neutrophils predominantly within 
the dura mater (Figure S2F), as well as the pia mater and the ependyma (data not shown) 
of the steady state CNS. Together, our analysis of the steady state CNS reveals multiple 
immune cell populations residing within CNS compartments, including a subset of 
microglia-like BAMs. 
 
3.2. BAMs are CNS-Resident Macrophages Distinct from Microglia 
We used our mass cytometry data to design a 22-color antibody panel for fluorescence 
cytometry (Table S1) which identified all the major leukocytes in the CNS. This 
allowed us to use genetic reporter and fate-mapping experiments aimed at determining 
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the relationship between BAMs, microglia and CNS DCs. To compare the mass- and 
fluorescence cytometry datasets and their ability to identify the same cell populations, 
we employed force-directed analysis to generate a Scaffold map (Spitzer et al., 2015): 
we first modeled a reference map of CNS leukocytes from our mass cytometry data, 
using manually gated populations as landmark nodes (in colors), and the initial 100 
FlowSOM nodes (before metaclustering) as unsupervised nodes (in gray) (Figure 2A). 
Mapping the flow cytometry data onto this mass cytometry-based reference map 
showed that cells within unsupervised nodes that grouped around the landmark nodes 
had the expected expression profiles and were present at similar frequencies to those in 
the original reference map (Figure 2B and 2C). 
We then examined cells from the CNS of Sall-1GFP reporter mice (Buttgereit et al., 
2016). Only microglia from these mice expressed the GFP reporter, and not BAMs or 
cDCs (Figure 2D and 2E and as a clustered t-SNE in S3A). Thus, in addition to the 
phenotypic distinctions between BAMs and microglia revealed by mass-cytometry, we 
confirmed Sall1 as a key transcription factor, which can be used to distinguish these 
closely-related cell populations. 
Microglia and the majority of BAMs are long-lived (Goldmann et al., 2016) while DCs 
are bone-marrow derived and short-lived (Merad and Manz, 2009). To assess the 
longevity of our identified populations, we used Cx3cr1CreER Rosa26-RFP inducible 
fate-map mice where tamoxifen induces irreversible expression of red fluorescent 
protein (RFP) in CX3CR1+ cells (Yona et al., 2013). Short-lived labeled cells will be 
replaced from unlabeled bone marrow progenitors, while long-lived or self-renewing 
cells will remain RFP+. Here, 5 weeks after tamoxifen treatment of adult Cx3cr1CreER 
Rosa26-RFP mice, less than 5% of monocytes were RFP+, as expected (Figure S3B), 
while almost 80% of microglia, 50% of BAMs, and less than 10% of DCs were RFP+ 
(Figure 2F and 2G). Most BAMs retain the RFP label, as a result of the earlier 
tamoxifen treatment, whereas most DCs lose RFP expression. Hence, we conclude that 
CX3CR1+ BAMs are replaced more slowly than CX3CR1+ DCs. This differential 
longevity confirms that the high-dimensional map produced here corresponds to the 
predicted ontogeny of CNS leukocytes. 
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Figure 2. Identification of Microglia and BAMs by Genetic Targeting. (A) A Scaffold 
reference map of the steady-state adult CNS leukocyte landscape constructed from mass 
cytometry data displaying 100 unsupervised FlowSOM nodes and manually-gated landmark 
nodes. (B) Fluorescence cytometry data of steady-state adult CNS leukocytes mapped onto the 
reference map created in (A). (C) Representative fluorescent marker expression in the Scaffold 
map. (D) CD45+ CNS leukocytes (left) and frequency of GFP+ cells (right) in Sall1GFP+/- reporter 
mice (n = 3, representative of two independent experiments). (E) GFP expression overlaid onto 
the Sall1GFP+/- Scaffold map. (F) CD45+ CNS leukocytes (left) and frequency of RFP+ cells 
(right) in Cx3cr1CreER Rosa26-RFP mice 5 weeks after tamoxifen treatment. (n = 5, showing 4 
pooled experiments). (G) RFP expression overlaid onto the Cx3cr1CreER Rosa26-RFP Scaffold 
map. See also Figure S3. Error bars represent range. 
 
 
 
3.3. Enrichment of BAM Subsets in Distinct CNS Compartments 
Now that we could reliably discriminate BAMs from microglia and DCs we conducted 
an in-depth BAM phenotype analysis. This revealed expression of the macrophage-
associated markers MerTK, CD64 and F4/80, as well as CD16/32 (Figure 3A), and 
absence of the DC, monocyte and microglia markers CD11c, Ly6C  
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Figure 3. In-depth Characterization of the Phenotype and Localization of CNS BAMs. 
(A) CNS BAMs were plotted onto a separate t-SNE. Outlined plots represent four 
distinguishing markers of BAM subsets. (B) BAMs clustered into four subsets based on the 
entire panel of markers. (C) Expression of CD38, MHCII, CCR2 and CD206 by the four BAM 
subsets (colored). (D) Relative frequencies of the four BAM subsets across 3 mice (n = 3, 
representative of 4 independent experiments). (E) Median expression of mass cytometry 
markers on each BAM subset and microglia. (F) One-SENSE analysis of BAMs along lineage 
and activation profiles. (G) Fluorescence cytometry data depicting expression of Lyve1, CD38 
and MHCII in three BAM subsets. (H) Density of BAM subset occurrence within each region 
of interest (ROI) (n ≥ 5 mice, ROI ≥ 4 per mouse). See also Figure S4. Error bars represent the 
median ± SEM. 
 
 
 
and Siglec-H, respectively. We identified four BAM subsets based on differential 
expression of CD38, MHCII and CCR2: subset 1 (CD38+MHCII-CCR2-), subset 2 
(CD38+MHCII+CCR2-), subset 3 (CD38-MHCII+CCR2-), and subset 4 (CD38-
MHCII+CCR2+) (Figure 3B and 3C). The median expression values of each marker in 
the different BAM subsets are compared in a heatmap (Figure 3D). The majority of 
BAMs (75.7 ± 1.2%) were located within subset 1, while subsets 2, 3 and 4 comprised 
7.6 ± 0.8%, 7.2 ± 0.2% and 9.4 ± 1.2% of total BAMs, respectively (Figure 3E). 
Clusters 3 and 4 are very similar and because they essentially differ only in the amount 
of CCR2 expression. To understand the full heterogeneity and distinct high-
dimensional phenotypes of the four BAM subsets at the single-cell level, we employed 
categorical One-SENSE analysis (Cheng et al., 2016), where the y-axis represents the 
lineage profile, the x-axis represents an activation marker profile (Figure 3F), and co-
regulation of marker expression is also shown, e.g. CD206 expression is high on subset 
1 but decreases as the activation markers MHCII and CD44 increase towards subsets 2, 
3 and 4 while high expression of other macrophage markers like CD64 are maintained. 
We then used confocal microscopy to ask whether these subsets are enriched in specific 
compartments of the CNS. The available anti-mouse CD38 performs poorly in IHC, 
however using fluorescence cytometry we found that Lyve-1 and CD38 expression 
closely overlap (Figure 3G and S4A) and therefore that Lyve-1 was a suitable surrogate 
for CD38 on BAMs. Since lymphatic vessels also express Lyve-1 and are present in the 
dura mater (Louveau et al., 2015), we also stained for collagen IV, which is expressed 
on vessels but not BAMs. Combining Lyve1 or MHCII with the macrophage marker 
Iba-1, we located BAMs within the pia mater, perivascular space, choroid plexus and 
dura mater and showed that they express CD206, as previously shown (Figure S4B). 
By histology, we identified three BAM subsets in these regions using differential Lyve1 
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and MHCII expression (Figure S4C). The initial CyTOF-identified subsets 3 and 4 are 
merged here. Of note, Lyve-1+MHCII+ (subset 2) BAMs were enriched in the pia mater 
and perivascular space, whereas the dura mater harbored relatively more single-positive 
MHCII+ BAMs (subsets 3 and 4) and few Lyve-1+MHCII+ BAMs (Figure 3H). The 
choroid plexus contained a similar frequency of each of the three BAM subsets. Single-
positive Lyve1+ BAMs (subset 1) were present in all locations. Interestingly, only 
MHCII+ BAMs, enriched in the choroid plexus and dura mater, expressed CCR2+ 
(Figure 3B) (subset 4), consistent with their proposed high turnover rate from CCR2+ 
bone marrow cells (Goldmann et al., 2016). These phenotypic variations of BAMs 
across the CNS may reflect functional differences and could be shaped by cues from 
their specific local microenvironments. 
 
3.4. Heterogeneous Subsets of DCs Exist in the CNS 
Besides BAMs, DCs also localize in the CNS border regions and are considered to be 
the prime APCs at these sites (Anandasabapathy et al., 2011; Greter et al., 2005). In 
other tissues, DCs exist as functionally and phenotypically distinct subsets but little is 
known of the DCs associated with the CNS. We used our mass cytometry data to 
perform an in-depth phenotypic characterization of CNS-associated DCs (Figure 4A). 
We identified three main DC subsets corresponding to cDC1s, cDC2s and pDCs 
(Figure 4B), differentiated by their expression of CD11b (or CD172) and CD24 (Figure 
4C). In addition, Ly6C, B220 or Siglec-H confirmed the pDC identity of subset 6. The 
cDC2 population was heterogeneous and could be further separated into CD24+CD206+ 
cDC2 (subset 1), CD24-CD64+/lowCD206-/low cDC2 (subset 2), CD135hi cDC2 (subset 
3) and PDL1+ cDC2 (subset 4); while cDC1s (subset 5) were 
CD11blowCD172lowCD24+CD135hiCD117+ (Figure 4D). As in most other organs 
(Guilliams et al., 2016), cDC2s were relatively more abundant than cDC1s (Figure 4E). 
The lineage markers and activation profiles of these subsets were again fully revealed 
using categorical One-SENE (Figure 4F). We localized CD11c+MHCII+ DCs of the 
CNS by confocal microscopy only in the choroid plexus, pia mater and dura mater, and 
not in the perivascular space (Figure 4G), suggesting that these DC-enriched 
compartments may serve as entry sites for MHC-dependent T cells. 
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Figure 4. Dendritic Cell Heterogeneity in the Steady-State CNS. (A) CNS DCs were plotted 
onto a separate t-SNE. Selected plots represent four chosen distinguishing markers. (B) DCs 
clustered into three major subsets based on the entire panel of markers. (C) Expression of 
distinguishing markers by the DC subsets. (D) Relative abundance of the DC subsets within 
total CNS DCs across 3 mice (n = 3, representative of at least 3 experiments). (E) Median 
expression of mass cytometry panel markers on each DC subset. (F) One-SENSE analysis of 
DCs by their lineage and activation profiles. (G) Representative fluorescence 
immunohistochemistry images of DCs in the pia mater, choroid plexus and dura mater (n ≥ 2 
mice, ≥ 3 sections per mouse). (H) cDC1 and cDC2 response to the indicated stimuli. (I) IRF4 
and IRF8 expression by cDC1s and cDC2s. 
 
 
 
Since we have shown that CNS cDC2s exist with some heterogeneity in their surface 
phenotype, we sought to confirm their inherent identity compared to cDC1s. Both 
cDC2s and cDC1s expanded to a similar extent with Flt3L treatment (Figure 4H) and 
moreover cDC1s were IRF8hiIRF4int and cDC2s were IRF8-IRF4hi (Figure 4I), as 
previously predicted (Guilliams et al., 2016). The apparent heterogeneity of cDC2s has 
also been noted at other organs such as the lung (Schlitzer et al., 2013a) and heart 
(Clemente-Casares et al., 2017). 
 
3.5. Aging and AD Change the CNS Myeloid Cell Landscape 
Aging has profound effects on the entire CNS landscape. We therefore asked how the 
immune cell populations in the CNS changed in aged mice by comparing geriatric mice 
aged 1.5 years with younger adult mice aged 2 months. We first noted a dramatic 
increase in the frequency of T cells from 1.5 ± 0.9% in adult mice to 11.1 ± 4.2% in 
geriatric mice, while NK T cells and pDCs were significantly less frequent in geriatric 
mice (Figures 5A and 5B). We also observed an increased frequency of 
CD38+MHCII+CCR2- and CD38-MHCII+CCR2- BAMs and a corresponding decrease 
in CD38+MHCII-CCR2- and CD38-MHCII+CCR2+ BAMs in geriatric mice (Figure 
5C); alongside, the frequency of CD24+ cDC2s decreased, while CD135+ cDC2s were 
more abundant in geriatric mice (Figure 5D).  
Strikingly, we found a phenotypic signature in a subset of microglia in geriatric mice 
which expressed high levels of CD11c and CD14 (Figure 5E). Aging is a major risk 
factor for neurodegenerative diseases, and changes in microglial morphology precede 
pathology in Alzheimer’s patients (Perry and Holmes, 2014; Streit et al., 2009). We  
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Figure 5. Aging Alters the CNS Immune Landscape. (A) Non-microglial CNS leukocytes 
from adult (2-month-old) and geriatric (1.5-year-old) C57BL/6 mice analyzed by mass 
cytometry. Frequencies of (B) non-microglial CNS leukocytes, (C) BAM and (D) cDC subset 
distributions in adult and geriatric mice. (E) Normal and reactive microglia differentiated by 
CD14 and CD11c expression in adult and geriatric mice (n = 3). (F) Normal and reactive 
microglia in 4-month-old WT and APP/PS1 mice (n = 2-4, experiment repeated twice). (G) 
Frequencies of age- or AD-associated microglia in adult vs. geriatric C57BL/6 mice, or the 
cortex (plaque-harboring) and cerebellum (internal control) of WT vs. APP/PS1 mice, 
respectively. (H) Median expression of myeloid markers in the mass cytometry panel between 
normal and age-associated microglia in C57BL/6 adult and geriatric mice (corrected p-value < 
0.5 if significant). ** = p-value significant with a Benjamini-Hochberg (BH) false discovery 
rate (FDR) < 5%. Error bars represent range except in (H) where error bars represent the median 
± SEM. n.s. = not significant. See also Figure S5. 
 
 
 
therefore asked whether the age-related changes in leukocyte populations and the age-
associated microglial phenotype in particular were present in a murine model of 
Alzheimer’s disease. We compared the plaque-harboring cortex with the non-plaque-
harboring cerebellum (internal control) of 4-month-old APP/PS1 mice (Radde et al., 
2006a; Vom Berg et al., 2012), and age-matched WT littermates (external control). We 
found that, as in much older geriatric mice, the frequency of T cells was increased in 
the plaque-harboring cortex of AD-prone mice (Figure S3A); while, in contrast to 
geriatric mice, the subset distribution of BAMs was unaltered in AD-prone mice 
(Figure S3B), suggesting it to be a phenomenon observed during normal aging. 
Of note, we also detected a phenotypic signature in a subset of microglia in AD-prone 
mice that resembled microglia in geriatric mice in the expression of CD11c and CD14, 
and which was absent in WT littermate controls (Figure 5F). Approximately 11.9 ± 
6.5% of microglia had this signature in geriatric mice, compared to virtually zero in 
young adult mice, and approximately 13.2 ± 1.7% in the plaque-bearing cortex of AD-
prone mice, while these cells were almost undetectable in the unaffected cerebellum 
and in WT littermate cortex or cerebellum (Figure 5G and S3C). A similar subset of 
microglia was also found by Keren-Shaul and colleagues by sc-RNAseq in 5XFAD 
mice (Keren-Shaul et al., 2017). We located these CD11c+ microglia around Ab plaques 
in APP/PS1 mice (Figure S3D). The full reactive signature of these microglia shows 
that, in addition to increased phagocytosis-associated markers CD11c and CD14, there 
was an accompanying increase in activation markers CD86 and CD44 and the 
inhibitory ligand PDL1 (Figure 5H). MHCII expression increased slightly while 
expression of microglial inhibitory-checkpoint markers CX3CR1, MerTK and Siglec-
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H decreased. This phenotypic change within the small age- and AD-associated subset 
represents a switch from a homeostatic microglial program to a ‘reactive’ signature that 
displays an activated, phagocytic profile (Hanisch and Kettenmann, 2007; Krasemann 
et al., 2017). 
 
3.6. CNS Invasion and Resident Myeloid Cell Activation During Autoimmune 
Neuroinflammation 
We induced EAE in adult C57BL/6 mice and compared the cellular composition of the 
CNS at the peak of disease with steady state control mice (Figure 6A and Figure S6A). 
Analyzing the frequencies (Figure 6B and S6C) and cell numbers (Figure S6C) of CNS 
leukocytes, we found that the majority of infiltrating cells were MdCs, closely followed 
by T cells. 
Microglia were highly reactive during EAE and exhibited a markedly different 
phenotypic signature than in the steady state, as evidenced by their change in 
localization on the t-SNE map (Figure 6A). The microglial identity of these highly 
reactive cells during EAE was confirmed in Sall1GFP reporter mice (Figure 6C and 
Figure S6D). We then conducted an in-depth analysis of the phenotypic changes in 
microglia in response to EAE inflammation: once again expression of microglial 
inhibitory-checkpoint markers CX3CR1, MerTK and Siglec-H was reduced, and 
expression of markers CD44, CD86, PDL1 and CD11c increased, as similarly observed 
in geriatric mice. However, in contrast to age- and AD-associated microglia, CD14 
expression decreased during EAE and a dramatic increase in MHCII and Sca-1 was 
observed (Figure 6D, 6E and S6E). The conversion from the homeostatic microglial 
signature to the highly reactive state signature was also evident when comparing lineage 
and activation profiles using categorical One-SENSE (Figure 6F). Here and in the t-
SNE map (Figure 6A and S6E) there are very few EAE microglia that are located in 
the same area as steady-state microglia. With a dramatic shift in both the lineage and 
activation profiles, and in contrast to a small subset of reactive microglia in aging and 
neurodegenerative disease, the entire microglial population becomes homogeneously 
reactive during EAE. 
BAMs, MdCs, and DCs share a number of lineage markers. Interrogating their profiles 
more closely we found MdCs, monocytes and cDCs to be more similar to  
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Figure 6. Neuroinflammation Results in CNS Invasion and Complete Microglial 
Reactivity. EAE was induced in adult (2-month-old) C57BL/6 mice and CNS cells were 
analyzed by mass cytometry at the peak of disease, and in control steady-state mice. (A) 
Clustered leukocytes on a t-SNE map generated from the combined steady-state and EAE data 
(100,000 cells) (B) Frequencies of leukocytes within total CNS leukocytes in steady-state and 
peak EAE (n = 3, representative of 5 independent experiments). (C) CD45+ CNS leukocytes 
(left) from Sall1GFP+/- reporter and control mice at peak EAE, with quantification (right) of GFP+ 
cells (n = 3, representative of two independent experiments). (D) Median expression profiles 
of steady-state and peak EAE microglia. (E) Representative histograms showing highly up-
regulated makers between steady-state and peak EAE microglia. (F) One-SENSE analysis 
comparing the lineage and activation profiles of steady-state and peak EAE microglia. See also 
Figure S6. 
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each other while BAMs and pDCs were distinctly separated on the t-SNE map (Figure 
S7A). We used Cx3cr1CreER Rosa26-RFP EAE mice to validate that BAMs and MdCs 
were indeed identified correctly. At peak EAE, as in steady state, only microglia and 
BAMs were RFP+ (Figure 7A and S7B). However, the number of total and RFP+ BAMs 
decreased during EAE relative to steady state and BAMs became outnumbered by 
infiltrating MdCs (Figure 7B and S6C). As with microglia, the BAM phenotype was 
entirely altered in EAE (Figure 7C): inflammation led to increased expression of 
MHCII and the activation markers CD44 and Sca-1, as well as PDL1, CD117 and 
CD11c (Figure 7D). 
Ly6Chi monocytes invade the CNS parenchyma and differentiate into inflammatory and 
pathogenic MdCs during EAE (Codarri et al., 2013; Croxford et al., 2015a; Yamasaki 
et al., 2014). Ly6Chi monocytes did not yet undergo inflammation-induced phenotypic 
changes (Figure S7A), while MdCs were highly activated, expressing Sca-1, MHCII, 
PDL1, CD11a, CD86, CD38, CD14 and CD16/32 and a macrophage-like lineage 
profile (Figure 7E). This has previously rendered them hard to distinguish from 
microglia and BAMs. We also distinguished cDC subsets and pDCs and show their 
lineage and activation profiles during peak EAE (Figure 7F). 
Finally, we defined a myeloid panel of 12 markers within our mass cytometry data to 
clearly discern reactive microglia, BAMs, MdCs and cDCs even in the inflamed CNS 
(Figure 7G). Together, our analysis shows that CNS-resident myeloid cells become 
highly activated during neuroinflammation but can still be distinguished from 
macrophage-like invading MdCs, confirming the utility of our high-dimensional 
myeloid immune atlas as a valuable resource for marker combinations allowing 
mapping of cellular subsets in downstream analysis. 
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Figure 7. BAMs Lose their Heterogeneity during Neuroinflammation but are Still 
Distinguishable from MdCs and DCs.  (A) CD45+ CNS leukocytes (left) from Cx3cr1CreER 
Rosa26-RFP and control mice at peak EAE, with quantification (right) of RFP+ cells (n = 2, 
representative of two independent experiments). (B) Total numbers of BAMs, RFP+ BAMs and 
MdCs in steady-state and peak EAE Cx3cr1CreER Rosa26-RFP mice. (C) BAM subset tSNE 
analysis by mass cytometry between steady-state and peak EAE mice. (D) Highly up-regulated 
makers between steady-state and peak EAE total BAMs. (E) One-SENSE analysis of lineage 
and activation profiles of Ly6Chi monocytes, MdCs and Ly6Clow monocytes, and (F) DCs 
during peak EAE. (G) Expression levels of distinguishing markers between microglia, BAMs, 
MdCs and cDCs during peak EAE. *** = p-value significant with a BH FDR < 1%. Error bars 
represent range. See also Figure S7. 
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4. Discussion 
We have systematically and unambiguously characterized the entire leukocyte 
landscape within the mammalian CNS under a range of conditions. While lymphocyte 
populations can be readily identified via expression of unique canonical antigens, and 
recent reports have begun to characterize them in the steady-state CNS (Korin et al., 
2017), CNS myeloid cells have proven highly challenging to study. The CNS myeloid 
compartment is the largest CNS-resident immune cell pool and has been implicated in 
multiple aspects of CNS health and disease, including MS, AD, dementia and 
Parkinson’s disease, as well as psychiatric diseases and behavioral disorders like 
schizophrenia, autism and depression (Herz et al., 2017; Kettenmann et al., 2013). 
Using high-dimensional cytometry in combination with neural-network based 
algorithms, we identified microglia, BAMs, DCs, monocytes, neutrophils, eosinophils 
and mast cells as separate populations by extensive surface protein phenotyping. These 
data were corroborated by functional, genetic and fate-mapping approaches. Meningeal 
neutrophils were the third most abundant cell type within the steady state CNS. Since 
neutrophils are usually associated with inflammation, this was unexpected, but tissue-
resident neutrophils have been reported in the decidua, an immune barrier at the 
maternal-fetal interface and may be patrolling the steady state CNS or have a 
homeostatic role there (Amsalem et al., 2014; Shechter et al., 2013a). 
Being able to interrogate all the identified populations in the high-dimensional space 
led us to uncover four previously-uncharacterized BAM subsets, distinguished by 
differential expression of CD38/Lyve1, MHCII, and CCR2. These patterns of 
expression are also likely to have direct functional implications: CD38 functions in 
calcium signaling and is involved in FcgR-mediated phagocytosis (Kang et al., 2012) 
as well as immunosuppression (Chevrier et al., 2017b), while Lyve1 expression has 
also been found on embryonically derived cardiac macrophages which are crucial in 
cardiac repair (Epelman et al., 2014; Stevens et al., 2016). Analogous to CNS BAM 
subsets, resident macrophages in the testes, which has also limited immune 
surveillance, exist as a mixed population of embryonically-seeded CD64hiMHCII- and 
bone marrow-derived CD64lowMHCII+ cells, both expressing an immunosuppressive 
gene signature (Mossadegh-Keller et al., 2017). It will be interesting to discover 
whether the same applies to BAM subsets in the CNS where immune suppression in 
the steady state is also critical. Interestingly, the testicular CD64hiMHCII- macrophages 
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expressed relatively higher levels of IL-10, and lower levels of IL-1b than the 
CD64lowMHII+ macrophages (Mossadegh-Keller et al., 2017), suggesting that the latter 
play a more active role in inflammatory responses. Similar findings were reported in 
cardiac-resident macrophages (Epelman et al., 2014). Since BAM subsets can also be 
separated based on MHCII expression, MHCII+ BAMs may also have more potent 
immune-stimulatory functions compared to MHCII- BAMs. 
Using the markers CD38, or its surrogate Lyve1, and MHCII, we showed that while no 
BAM subset was exclusive to a particular CNS compartment, Lyve1+MHCII+ BAMs 
were enriched in the pia mater, perivascular space and choroid plexus. The dura mater 
distinctly lacked Lyve1+MHCII+ BAMs and harbored predominantly Lyve1-MHCII+ 
BAMs. As with most tissue-resident macrophages, including microglia (Gomez 
Perdiguero et al., 2015), BAMs of the pia mater, perivascular space and choroid plexus 
are seeded during embryogenesis either from the yolk-sac and/or the fetal liver 
(Goldmann et al., 2016), while the ontogeny of dural BAMs has not been described. By 
mass cytometry analysis we found that CD38-(Lyve1-)MHCII+ BAMs can also express 
CCR2, and which are located in the dura and choroid plexus. Therefore, dural and/or 
choroid plexus BAMs should also be MHCII+CCR2+. For the choroid plexus BAMs, 
this is in line with their gradual replacement with CCR2+ monocytes and may also apply 
to dural BAMs, likely representing a fresh hematopoietic myeloid cell to replace the 
dying BAMs which accumulate there. 
The stability of BAMs was previously (Goldmann et al., 2016) determined by imaging 
YFP+Iba1+ BAMs in a Cx3CR1CreER Rosa26-YFP fate-map system within their local 
compartments, however only 40% of pial BAMs were YFP+ compared to 80-90% of 
perivascular and choroid plexus BAMs (which decreased with time in the choroid 
plexus). Our data demonstrate that single positive CD38/Lyve1+ BAMs make up 
approximately 30% of pial BAMs, and that this profile can occur with low to absent 
CX3CR1 protein expression levels while other, MHCII+ BAM subsets expressed high 
levels of CX3CR1 are likely targeted better in this system. This may explain the lower 
targeting of pial BAMs in the Cx3CR1CreER Rosa26-YFP fate-map system. Therefore, 
in order to fully target pial BAMs the Cx3CR1CreER Rosa26 fate-map system is likely 
to be inadequate. A targeting system utilizing the CD38 or CD206 promoters may prove 
to be more useful in tracking and manipulating the majority of BAM subsets, including 
pial BAMs. This is important particularly because the pia mater is reported to facilitate 
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entry of effector T cells during EAE via interaction with pial BAMs (Schläger et al., 
2016), however the distinction between macrophages and DCs in this study was not 
clear. The function of the phenotypically different dural BAMs in CNS homeostasis 
and disease likely also differs from pial, perivascular and choroid plexus BAMs as the 
dura is not in physical contact with the brain and encloses a lymphatic system within 
its sinuses. The differential surface proteome of BAM subsets and their enrichment 
within specific CNS compartments may be related to their different roles in these 
microenvironments. Importantly, by defining a detailed surface protein profile of 
BAMs and their subsets, it will now be possible to purify these cells for detailed study. 
It will be interesting to discover their gene signatures and functions within the different 
CNS compartments, and to determine whether they are shaped by their particular 
microenvironment or whether fate is dictated by ontogeny. 
Besides BAMs, we were also able to discern multiple subsets of DCs, including cDC1, 
cDC2 and pDC subsets within the steady-state CNS. A clear distinction between DCs 
and BAMs has not been easy in the past and has led to claims regarding superior APC 
capacities of both DCs (Greter et al., 2005) and BAMs (Schläger et al., 2016). With our 
resource, it is now possible to unambiguously discern BAMs from DCs using specific 
markers, and therefore to target them in functional studies. Adding to the complexity 
of assigning APC function within the CNS, DC subsets have distinct pattern recognition 
receptor signatures and are thought to induce specific adaptive immune responses 
(Schlitzer et al., 2015). Future studies will be needed to determine whether/which of 
the identified CNS DC subsets sample CNS antigens and migrate to the draining 
cervical lymph nodes to activate naïve T cells; this is relevant both during CNS 
infections and in neurodegeneration, where pathogenic protein aggregates accumulate 
within the CNS parenchyma and meninges (Kalaria et al., 1996). The immune-
stimulatory functions of pDCs, cDC1s and cDC2s within peripheral organs may not 
apply to the CNS, where presumably immune suppression rather than activation is 
critical to avoid disruption of brain function. Interestingly, it was recently reported that 
in the human fetus, where immune activation would be critically harmful, cDC1s and 
cDC2s perform normal migratory and antigen sampling functions but promote Treg 
induction and actively inhibit T helper cell activation through tolerogenic mechanisms 
(McGovern et al., 2017). Whether a similar role can be assigned to CNS DCs during 
homeostasis remains to be determined. 
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We extended our analysis to pathologic processes of aging and neurodegenerative 
disease. Aging, characterized by some degree of inflammation (Deleidi et al., 2015), 
had a dramatic impact on CNS-resident phagocytes. Importantly, we identified a 
specific subset of microglia associated with aging which had a reactive phenotype 
characterized by up-regulation of phagocytic and activation/inhibition markers, and 
with down-regulation of microglial inhibitory-checkpoint markers. In a model of 
Alzheimer’s disease, microglia with the same signature were observed even in 
relatively young mice; thus, microglial changes observed during aging and AD-like 
pathology in APP/PS1 mice may not represent a cell intrinsic program, but rather a 
specific response to cues from the local microenvironment. These cues may to some 
extent be similar in geriatric and APP/PS1 mice, for example age-related myelin 
fragmentation (Safaiyan et al., 2016), age- and AD-related protein accumulation 
(David, 2012) and neurodegeneration (Wyss-Coray, 2016) as well as increased 
inflammatory mediators (Deleidi et al., 2015; Heppner et al., 2015).  
A recent report using single cell RNA sequencing of microglia in the 5XFAD mouse 
model for AD and in the SOD1G93A mouse model for amyotrophic lateral sclerosis 
(ALS) showed that similar disease-associated microglia appear with disease 
progression and up-regulate genes involved in lipid metabolism and phagocytosis, 
including Itgax (CD11c, confirmed in our data) (Keren-Shaul et al., 2017). However, 
regulation of mRNA and the encoded protein can differ dramatically and sc-RNAseq 
will, depending on the analysis depth, only detect abundant transcripts (Peterson et al., 
2017). In support of this notion, many of the proteins we and others use to describe the 
CNS immune landscape did not overlap with the public sc-RNAseq data 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE98969) (Keren-Shaul et al., 
2017). Thus, our analysis uniquely provides surface protein markers, which can be 
targeted with commercially available mAbs, enabling cell isolation for further studies. 
Furthermore, this disease-associated microglial signature was shown to be regulated by 
the TREM2-APOE pathway across different CNS pathologies, including in APP/PS1 
and SOD1G93A mice, and is initiated by phagocytosis of degenerating apoptotic neurons 
(Krasemann et al., 2017). These studies made us of genetic and morphological analyses 
to identify these disease-associated microglia. 
We also deeply characterized the aggressively inflamed EAE CNS in which the 
leukocyte composition is changed due to the influx of inflammatory leukocytes, termed 
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infiltrating or invading cells. A recent report (Korin et al., 2017) suggested that all cells 
that are not CD45low myeloid cells in the steady state are CNS-infiltrates. However, this 
study does not take into account that leukocytes in the steady state CNS are not truly 
parenchymal infiltrating cells as CNS infiltration is accompanied by inflammation. 
Furthermore, they proposed CD44 as a distinguishing marker for CNS-infiltrating cells 
during inflammation, whereas we found CD44 to be clearly expressed by CNS-resident 
leukocytes and is further up-regulated by microglia and BAMs during EAE, and by 
age- and AD- associated microglia. Hence, CD44 is a poor marker for invading vs. 
resident cells as a result of the inflammatory changes. 
During EAE, CNS-infiltrating monocytes and their pathogenic progeny, MdCs, could 
not previously be distinguished from reactive microglia and other resident phagocytes 
as conventional approaches cannot resolve their largely-overlapping phenotypes. We 
were able to discriminate subsets of infiltrating and resident myeloid cells during EAE, 
and uncovered a massive influx of infiltrating T cells, monocytes and MdCs in the EAE 
brain. These MdCs displayed a homogenous macrophage-like phenotype, consistent 
with their proposed role in myelin degradation and phagocytosis during EAE (Spath et 
al., 2017; Yamasaki et al., 2014). In contrast to high numbers of MdCs and cDCs, total 
cell numbers of BAMs decreased during EAE, in agreement with report describing that 
tissue-resident macrophage numbers decline with the influx of peripheral inflammatory 
monocytes, but later self-renew once the inflammation is resolved (Davies et al., 2013). 
At peak disease, BAMs almost exclusively expressed an inflammation-associated 
signature, characterized by co-expression of CD38 and MHCII, and lack of CCR2. This 
BAM signature was also seen in geriatric mice, but to a lesser extent. Future studies 
addressing the plasticity of BAM subsets will determined whether this loss of 
heterogeneity and expression of a universal CD38+MHCII+ phenotype during 
inflammation is due to individual subset changes or outnumbering by proliferating 
CD38+MHCII+ BAMs already present at steady state. 
In EAE, microglia became skewed towards a highly reactive phenotype, with a 
reduction in microglial inhibitory-checkpoint marker expression. The reactive 
phenotype seen during EAE bore similarities to the AAM signature in aging and 
APP/PS1 mice, and may in part represent a universal disease-associated microglial 
signature, as recently proposed (Krasemann et al., 2017; Zrzavy et al., 2017). However, 
EAE microglia also differed from the phenotype seen in aging and AD-prone mice: for 
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example, EAE microglia dramatically up-regulated expression of MHCII and Sca-1, 
both IFNg-responsive genes, which may reflect an increased potential for activating T 
cells. Strikingly, the entire microglia population in the brain parenchyma during EAE 
homogeneously change to display a highly reactive phenotype, compared to a small 
subpopulation of microglia which responds to aging and amyloidosis. This is likely due 
to the cytokines and other inflammatory mediators delivered to the CNS by invading 
leukocytes and suggests that inflammatory lesions in EAE affect microglia across the 
brain parenchyma even if accumulating lesions are distant in the spinal cord. In fact, 
activation of microglia in so-called “normal-appearing white matter” in the cortex of 
MS patients has been well documented (Vercellino et al., 2017). In contrast, during 
aging and amyloidosis, the vast majority of microglia do not respond and/or contribute 
to the pathogenesis, supporting the notion that age-associated changes do not lead to 
the massive immune cell influx into the CNS as seen in diseases such as EAE and MS. 
Taken together, our atlas identified novel subsets of BAMs, steady-state and reactive 
microglia, and CNS DC subsets. We confirmed the identities of each population by 
reporter- and fate-mapping, ontogeny and responsiveness to growth factors. Using our 
steady-state map to interrogate the same leukocytes during pathology, we defined 
robust signatures for BAMs and microglia during aging, neurodegeneration and 
neuroinflammation. This atlas can now be used to target and isolate CNS leukocyte 
subsets with cell-surface protein markers in steady state and their specific disease-
associated forms across pathologic conditions, thus enabling further studies into the 
role of these important cells in maintaining CNS homeostasis and in the initiation or 
resolution of CNS disease.  
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5. Supplementary tables and figures 
5.1. Table S1. Antibody Panels used to Interrogate the CNS Immune Landscape 
by Mass and Flow Cytometry, and Immunohistochemistry. 
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5.2. Figure S1. Identification of CNS Resident Leukocytes, Related to Figure 1. 
. 
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Figure S1. Identification of CNS Resident Leukocytes, Related to Figure 1. (A) 
Mass cytometry panel markers overlaid onto the t-SNE from Figure 1(A) of steady-
state adult CNS leukocytes. (B) Manual gating of mass cytometry data on major 
leukocyte populations. 
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5.3. Figure S2. Tracking blood leukocytes in the CNS, Related to Figure 1. 
Figure S2. Tracking blood leukocytes in the CNS, Related to Figure 1. (A) 
Intravascular leukocyte tracking by administering anti-CD45-PE i.v. with sacrifice and 
perfusion after 3 minutes, CNS isolation and single cell staining with fluorescence 
cytometry mAbs which included a second anti-CD45 in AF700. (B) Peripheral blood 
and (C) CNS leukocytes after anti-CD45-PE or isotype administration. Quantification 
of labeled intra-vascular cells (red) and unlabeled tissue-resident cells (purple) by total 
numbers (D) and frequencies (E) (n = 3, representative of 3 independent experiments). 
(F) Localization of CNS-resident neutrophils in the dura and pia mater in 4 µm sections 
of decalcified skulls with intact CNS (green = Ly6G, red = vWF (Von Willebrand 
Factor vessel marker), blue = DAPI) and DAB staining (brown = Ly6G).  
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5.4. Figure S3. Identification of Microglia and BAMs by Genetic Targeting, 
Related to Figure 2. 
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Figure S3. Identification of Microglia and BAMs by Genetic Targeting, Related to 
Figure 2. (A, top panel) t-SNE map and clustering of the steady-state adult CNS in 
Sall1GFP+/- mice using 22-color fluorescence cytometry (left); GFP, MerTK and CD206 
expression overlaid onto the t-SNE map (right). (Bottom panel) Representative gating 
for GFP+ microglia and BAMs. (B) Frequency of RFP+ Ly6Chi-lo monocytes in the 
blood following tamoxifen administration on day 0 and day 2 in Cx3cr1CreER Rosa26-
RFP mice. (C, top panel) t-SNE map and clustering of the steady-state adult CNS in 
Cx3cr1CreER Rosa26-RFP mice, 5 weeks after tamoxifen administration, using 22-color 
fluorescence cytometry (left); GFP, MerTK and CD206 expression overlaid onto the t-
SNE map (right). (Bottom panel) Representative gating for RFP+ microglia and BAMs. 
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5.5. Figure S4. Localizing BAM subsets within CNS compartments, Related to 
Figure 3. 
 
Figure S4. Localizing BAM subsets within CNS compartments, Related to Figure 
3. (A) Frequencies of BAM subsets determined by using CD38 or Lyve1. (B) 
Representative images showing co-labeling of MHCII and Lyve1 with CD206 and in 
relation to collagen+ vasculature in the indicated regions of the CNS. (C) Representative 
images showing Lyve1+, Lyve1+MHCII+ and MHCII+ BAM subsets in the indicated 
regions of the CNS. mMf = meningeal macrophage; pvMf = perivascular macrophage; 
cpMf = choroid plexus macrophage; dMf = dural macrophage. 
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5.6. Figure S5. In-depth Characterization of the CNS Leukocytes in a Mouse 
Model for Alzheimer’s Disease, Related to Figure 5. 
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Figure S5. In-depth Characterization of the CNS Leukocytes in a Mouse Model 
for Alzheimer’s Disease, Related to Figure 5. (A, left) Complete analysis of non-
microglial CNS leukocytes between 4-month-old WT and APP/PS1 mice (cortex and 
cerebellum combined) depicted in the t-SNE map with clustered cell populations and 
(right) their frequencies compared between the WT and APP/PS1 cortex and 
cerebellum. (B) BAM subset frequencies between WT and APP/PS1 cortex and 
cerebellum. (C) Differential t-SNE map of AD-associated and normal microglia 
between WT and APP/PS1 cortex and cerebellum. (D) AD-associated microglia located 
around Ab plaques in APP/PS1 mice. 
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5.7. Figure S6. EAE-induced CNS Invasion by Peripheral Leukocytes and 
Reactivity of Microglia, Related to Figure 6. 
 
Figure S6. EAE-induced CNS Invasion by Peripheral Leukocytes and Reactivity 
of Microglia, Related to Figure 6. (A) Median marker expression profile of CNS 
leukocytes of adult C57BL/6 mice at peak EAE. (B) Cell frequency and (C) number 
comparison of steady-state CNS-resident and peak EAE invading leukocytes. (D, left) 
t-SNE of all CNS leukocytes in Sall1GFP+/- mice at peak EAE, measured by fluorescence 
cytometry. (right) GFP and MerTK expression overlaid onto the t-SNE map. (E, see 
following page) Myeloid cell marker expression by steady-state resting microglia and 
peak EAE activated microglia on a t-SNE map generated using the combined microglia 
dataset. 
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	68	
5.8. Figure S7. Differentiating Invading Monocytes from BAMs and DCs during 
EAE, Related to Figure 7. 
 
Figure S7. Differentiating Invading Monocytes from BAMs and DCs during EAE, 
Related to Figure 7. (A) t-SNE depiction and marker expression showing distinction 
of non-microglial myeloid cell clusters from steady-state and peak EAE CNS. (B, left) 
t-SNE of all CNS leukocytes in Cx3cr1CreER Rosa26-RFP mice at peak EAE, measured 
by fluorescence cytometry. EAE was induced 5 weeks after tamoxifen administration. 
(right) RFP and CX3CR1 expression overlaid onto the t-SNE map. ** = p-value 
significant with a BH FDR < 5%. Error bars represent range. 
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6. Methods 
6.1. Experimental procedures 
6.1.1. Mice 
C57BL/6 (wild-type) mice were purchased from Janvier Laboraories and were taken to 
adulthood at 8 weeks of age or to geriatric age at 1.5 years of age and tissues were 
harvested together. Sall-1GFP reporter mice were described previously (Yuri et al., 
2009). Cx3cr1CreER Rosa26-RFP fatemap mice were kindly provided by S. Jung 
(Weizmann Institute of Science) (Yona et al., 2013). Heterozygous APP/PS1 mice 
which overexpress the familial AD mutant form of human APP (the Swedish mutation, 
K670N/M671L) and PS1 (M146L/L286V) transgenes under the transcriptional control 
of the neuron-specific mouse Thy-1 promoter (Radde et al., 2006b), and littermate 
controls, aged 4 months were kindly provided by F. Heppner (Charité–
Universitätsmedizin Berlin). All animal experiments performed in this study were 
approved by the Cantonal Veterinary Office Zurich. 
 
6.1.2. In vivo treatments and EAE induction 
Anti-CSF1R (clone AFS98) (Sudo et al., 1995) was administered by intraperitoneal 
(i.p.) injection on day 0 (2 mg) and day 2 (1 mg), diluted in PBS, and mice were 
euthanized on day 9. A 10 µg dose of Flt3L was administered i.p. daily for 9 days, after 
which mice were euthanized. Tamoxifen (Sigma) was dissolved in ethanol and corn oil 
to 25 mg/ml and administered in 200 µl doses via oral gavage (5 mg/dose) to 
Cx3cr1CreER Rosa26-RFP mice every second day for 8-10 days. After 5 weeks mice 
were either euthanized or immunized for EAE induction: Cx3cr1CreER Rosa26-RFP 
mice (5 weeks after tamoxifen administration) or C57BL/6 mice (aged 8 weeks) were 
injected with MOG35-55 peptide emulsified in Complete Freund’s Adjuvant sub-
cutaneously (s.c.) and Pertussis toxin (List Biological Laboratories) i.p., and scored, as 
previously described (Mrdjen et al., 2017). Peak of disease was defined when mice 
reached a score of 3-4 at approximately 14 days after immunization. 
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6.1.3. Tissue harvesting and cell preparation 
Mice were sacrificed by injection of pentobarbital (50 µl at 300 mg/ml) i.p. and 
transcardiac perfusion was performed with PBS and heparin (5 u/ml). The CNS was 
harvested and the dura mater was removed from the skull and included in the sample. 
The complete CNS samples (including meninges and choroid plexus) were processed 
into single cells as previously described (Mrdjen et al., 2017): briefly, the CNS was cut 
into small pieces in an eppendorf tube and incubated with digestion buffer (RPMI 
supplemented with 2% FBS, 2 mM HEPES, 0.4 mg/ml Collagenase D and 2 mg/ml 
DNAse) for 30 minutes at 37°C, shaking. Enzymatic digestion was stopped with EDTA 
(5 mM), the sample was homogenized with a syringe and the homogenate was filtered 
through a 70 µm cell strainer. This was followed by gradient centrifugation with 30% 
Percoll (GE Healthcare Life Sciences) in PBS (v/v) (23’500 x g for 30 minutes at 4°C 
without brakes), removal of myelin with a suction pump and filtration to generate a 
single-cell suspension. The samples were then ready for staining with mass- or 
fluorescence cytometry antibodies. 
 
6.1.4. Mass cytometry 
Mass cytometry antibodies were either labeled in-house using antibody-labeling kits 
and protocols purchased from Fluidigm. Antibodies were individually titrated and 
optimized as into the final panel prior to use, ensuring that each parameter was 
informative. We used 5 palladium metal isotopes for live cell barcoding of samples 
with CD45 (Mei et al., 2015), while keeping CD45-147Sm as a common channel to 
clearly identify cells expressing varying degrees of CD45, such as microglia, as 
previously described (Mrdjen et al., 2017). Briefly, individual samples from steady-
state adult, steady-state geriatric and peak EAE adult C57BL/6 mice were incubated 
with respective CD45-Pd + CD45-147 Sm antibodies in PBS for 30 minutes at 37°C 
after which they were washed twice with FACS buffer (PBS supplemented with 0.5% 
BSA), then combined into composite samples. In another experiment, the forebrain and 
hindbrain were taken from 4-month-old APP/PS1 or littermate control mice, barcoded 
separately, and combined into composite samples. We used one barcoding CD45-Pd 
per group in combination with CD45-147 Sm in order to avoid epitope saturation and 
maintain signal intensity, and were therefore able to barcode 5 samples from separate 
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groups per composite sample. This was followed by incubation of the composite 
samples with the cocktail of primary panel antibodies (Table S1) for 30 minutes at 
37°C, washing with FACS buffer and then incubating with secondary antibodies for 20 
minutes at 4°C. After washing, samples were incubated with intercalating solution 
(Iridium (Sigma) in MaxPar Fix/Perm buffer (Fluidigm)) overnight at 4°C. Prior to 
acquisition, the samples were washed twice with FACS buffer and once with MilliQ 
water. Barcoded composite samples were acquired on a Helios mass cytometer 
(Fluidigm). Quality control and tuning processes on the Helios were performed on a 
daily basis before acquisition. Data from different days and across acquisition time was 
normalized by adding five-element beads to the sample immediately before acquisition 
and using the Matlab-based normalization software, as described previously (Finck et 
al., 2013). 
 
6.1.5. Fluorescence cytometry 
Samples were incubated with primary antibodies in PBS for 30 min at 4°C, washed 
with PBS and incubated with secondary antibodies for 20 min at 4°C. After washing, 
cells were fixed and permeabilized with 100µL BD Cytofix/CytopermTM (containing 
4.2% Formaldehyde) for 20 min at 4°C, and washed with Perm buffer (PBS with 0.1% 
saponin) before intracellular labeling which was performed for CD3, CD4 and CD8 in 
Perm buffer for 30 min at 4°C, with final washing in Perm buffer. Samples were 
resuspended in PBS and analyzed by flow cytometry with a FACSymphonyTM cell 
analyzer. Before acquisition, PMT voltages were adjusted manually in order to reduce 
fluorescence spillover, and single-stain controls were acquired for compensation matrix 
calculation. 
 
6.1.6. Tracking intra-vascular cells in the CNS 
In order to label intra-vascular cells within the steady state CNS we injected PE 
conjugated anti-CD45 (7.5 µg in PBS) i.v. into adult C57BL/6 mice and euthanized 
them after 3 minutes, performed transcardiac perfusion and harvested the CNS, as 
previously described (Anderson et al., 2014). Single cell suspensions were then stained 
with fluorescence cytometry antibodies. 
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6.1.7. Immunohistochemistry for BAMs 
C57BL/6 mice were transcardially perfused with PBS and heparin (5u/ml) followed by 
2-4% (wt/vol) paraformaldehyde (PFA) in 0.1 M phosphate buffer (pH 7.4). The CNS, 
excluding the dura mater, was further fixed for 6-12 hours at 4°C and rinsed with PBS 
followed by cryoprotection with 30% (wt/vol) sucrose in PBS. Samples were embedded 
in OCT (Medite). Cryo-sectioning was performed with a thickness of 12-30µm using a 
Hyrax C60 cryostat (Zeiss). The dura mater was fixed for 2-4 hours at 4°C followed by 
removal from the skull, direct placing onto superfrost plus slides (Thermo Scientific) 
and storage at -20°C. For quantification of BAM subsets, the choroid plexus was 
removed from the CNS after fixation and also directly placed onto slides. CNS tissue 
sections, dura mater and choroid plexus mounts were permeabilized by incubation in 
blocking solution (PBS supplemented with 0.2% Triton-X 100 and 5% normal goat 
serum) for 1 hour at room temperature. Sections and tissues on slides were labeled 
primary antibodies either at 4°C over night or at room temperature for 2 hours, and 
free-floating sections for 24-72 hours at 4°C in staining solution (PBS supplemented 
with 0.1% Triton-X 100 and 2% normal goat serum): anti-Iba1 (1:500), anti-MHCII 
(1:200), anti-Lyve1 (1:200), anti-CD206 (1:100) and anti-CD11c (1:40). After 
washing, samples were incubated either at 4°C overnight or for 1-2 hours at room 
temperature with the respective secondary antibodies (anti-rabbit, anti-rat, streptavidin, 
etc., 1:500-700). Washing was repeated and sections were mounted with 1 drop of IS 
mounting medium with DAPI (Dianova) or SlowFade Gold antifade reagent with DAPI 
(Invitrogen). Fluorescence photomicrographs were acquired on a Vectra3 (Perkin 
Elmer) fluorescence microscope using a x20 objective lens. Filters for AF488, AF546, 
AF647, AF 660 and DAPI were used for imaging tissues to facilitate subsequent 
unmixing of all colors according to their respective spectra. 
 
6.1.8. Immunohistochemistry for neutrophils 
Mice were transcardially perfused using 4% (wt/vol) PFA. The fur was removed and 
heads (including the skull and brain) were transferred into USEDECALC solution for 
6 days (MEDITE Cancer Diagnostics, USA) and decalcified using ultrasonic 
decalcifying automate USE 33 (Medite® GmbH, Switzerland). Specimens were 
subsequently sectioned into 3 µm slices and embedded in paraffin for further 
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histological processing. Antigen retrieval was performed on sections by microwave 
heating at 98°C for 15 min (microMED T/T Mega, Hacker-Milestone) in citrate buffer 
(0.01M citric acid, pH6).  
For brightfield immunostaining, endogenous peroxidases were neutralized by 
incubation in PBS supplemented with 3% H2O2, and non-specific binding blocked 
using PBS supplemented with 10% FCS. Tissue sections were incubated with anti-
Ly6G (1:1000). Bound primary antibody was visualized with biotin-labeled anti–rat 
antibody and streptavidin-peroxidase staining method using polymerized 3,3′-
diaminobenzidine (all reagents from Dako; Haemalaun counterstaining of nuclei). 
For immunofluorescence staining, non-specific binding was also blocked using PBS 
supplemented with 10% FCS. Sections were subsequently incubated with anti-Ly6G 
(1:500) and with rabbit anti-vWF antibody (1:1000). Bound antibodies were visualized 
with AF555–labeled donkey anti–rabbit (1:200) and Cy3-labeled goat anti–rat (1:200) 
secondary antibodies. Nuclei were stained with DAPI (1:5000). All antibodies were 
diluted in DAKO RealTM Antibody Diluent. 
 
6.2. Quantification and statistical analysis 
6.2.1. Pre-processing of mass and flow cytometry data 
For mass cytometry data live cells were exported by manual gating on Event_length, 
DNA (191Ir and 193Ir), and live cells (195Pt) using FlowJo software (Tree Star), as 
previously described (Mrdjen et al., 2017). Next, cells were assigned to their initial 
samples using Boolean gating in FlowJo. Background subtracted .fcs files were 
exported from FlowJo, imported into the R environment and transformed using an 
inverse hyperbolic sine (arcsinh) function with a cofactor of 5 (Bendall et al., 2011). 
For flow cytometry data, after compensation correction in FlowJo, live, single, 
background subtracted and compensated cells were exported by manual gating. 
Samples were not barcoded so debarcoding was not necessary. The appropriate 
transformation cofactors were determined by uploading the files into Cytobank 
(www.cytobank.org) (Kotecha et al., 2010) and using the Scales feature; thereafter 
transformation was carried out in Matlab and transformed files were imported into the 
R environment for further pre-processing and analysis. To equalize the contribution of 
each marker in subsequent automated data analysis steps of mass and flow cytometry 
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data, we performed percentile normalization (Levine et al., 2015), normalizing all data 
to the 99.9th – 99.99th percentile of the merged sample in each experiment, depending 
on the number of outliers present. This preserves inter-sample variability in maximum 
expression values, which might be biologically relevant, and normalizes inter-marker 
maximum expression values, while maintaining original staining indices. 
 
6.2.2. Automated population identification in high- dimensional data analysis 
Pre-processing of the raw data was followed by dimensionality reduction and 
visualization by t-Distributed Stochastic Neighbor Embedding (t-SNE) (Amir et al., 
2013; Mair et al., 2016; Van Der Maaten and Hinton, 2008) with parameters as listed 
in the figure legends, clustering with FlowSOM into initial 100 nodes (Van Gassen et 
al., 2015; Weber and Robinson, 2016), followed by expert-guided manual 
metaclustering using the t-SNE with overlaid marker expression values and a heatmap 
of median expression values of the initial automated 100 FlowSOM nodes (Hartmann 
et al., 2016). In some cases, major cell populations were separated for further clustering 
into subsets. When comparing different groups, for example steady state and EAE 
samples, the t-SNE and clustering analyses were performed on the combined data sets. 
Force- and landmark- directed maps were generated with a modified version of the 
Scaffold application (Spitzer et al., 2015), and landmark populations that were 
manually gated in FlowJo and exported. We used the 100 initial FlowSOM nodes as 
unsupervised Scaffold clusters instead of the built-in clustering algorithm of the 
Scaffold application. This allowed the validation of expert-guided manual 
metaclustering by the grouping of FlowSOM nodes around manually-gated landmark 
nodes in the Scaffold map. Categorical ONE-Sense analysis was performed in the R 
environment by generating a one-dimensional t-SNE axis using lineage or activation 
markers, and a progressive lineage or activation heatmap along each axis, which were 
then arranged side-by-side. Statistics were calculated using Student’s t-test and the 
Benjamini-Hochberg post-test for false discovery rates (FDR). Stars were assigned 
according to the FDR: * = significant (i.e. p-value < 0.5) with a FDR of 10%, ** = 
significant with a FDR of 5% and *** = significant with a FDR of 1%. 
 
6.2.3. Quantification of cells from immunohistochemistry 
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Semi-automated cell detection and quantification of BAM subsets was performed using 
the implemented Inform Software (Perkin Elmer). A minimum of 5 sections per 
compartment (dura mater, pia mater, perivascular space, choroid plexus), per mouse 
were analyzed and a minimum of 4 regions of interest per section. Images used for 
analyses were taken on the SP8 upright (Leica) with a 20× emulsion objective at 1024 
× 1024 pixels in xy. A pinhole size of 60 µm was used. Images were taken in frames 
with a line average of 16. DAPI and AF546 were detected in one sequence and AF488 
and AF647 were detected in a second sequence. Alternatively, images were taken 
sequentially with a SP5 Leica confocal laser scanning microscope (Leica) equipped 
with argon and helium lasers and the 40× (oil immersion, NA1.25) objective. Images 
were processed and merged by Imaris Imaging software (Bitplane). 
  
	76	
7. Acknowledgements 
First and foremost, I would like to thank Burkhard Becher for having me in the lab, 
providing me with many great opportunities in research topics, new methodologies, 
valuable collaborations and a thriving scientific environment to work in. I also thank 
him for giving me the freedom and trust to explore these opportunities, enduring my 
sometimes stubborn determination and guiding my progress with insight but without 
micro management. I have really learnt a lot during this time here, scientifically and 
personally, and value it immensely. 
 
I am also grateful to my Ph.D. committee members Bernd Bodenmiller, Christian Münz 
and Ari Waisman, who gave me useful comments and support during our annual 
committee meetings. 
 
I thank all our collaborators who provided data, advice and critical feedback for the 
manuscript resulting from this project, including Felix J. Hartmann, Bettina Schreiner, 
Sebastian Utz, Brian Leung, Iva Lelios, Frank L. Heppner, Jonathan Kipnis, Doron 
Merkler, and Melanie Greter. I would also like to thank Anto Pavlović who worked 
with me during his Masters thesis project and was an outstanding student. 
 
Additionally, I thank Florian Mair for teaching me many things about flow cytometry, 
mouse work, discussing many immunology related topics with me when I first arrived 
in the lab, and also for transferring to me my first project in the Becher lab. Thank you 
to Ines for heling me organize all the permits and documents during my time in Zurich. 
Thank you to my friends inside the lab for providing much needed fun times and 
silliness. 
 
I specially want to thank my family who always support me from anywhere in the world 
and from the beginning provided me with a strong foundation to pursue the things I 
love, even if they take me far away. Finally, I thank Felix for his enduring love and 
ability to make me smile no matter what. 
  
	77	
8. References 
Absinta, M., Ha, S.K., Nair, G., Sati, P., Luciano, N.J., Palisoc, M., Louveau, A., 
Zaghloul, K.A., Pittaluga, S., Kipnis, J., et al. (2017). Human and nonhuman primate 
meninges harbor lymphatic vessels that can be visualized noninvasively by MRI. 
Elife 6. 
Aguzzi, A., Barres, B.A., and Bennett, M.L. (2013). Microglia: scapegoat, saboteur, 
or something else? Science 339, 156-161. 
Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W., and Rossi, F.M. (2007). Local self-
renewal can sustain CNS microglia maintenance and function throughout adult life. 
Nature Neuroscience 10, 1538-1543. 
Amir, E.-a.D. (2014). THESIS: viSNE and Wanderlust, two algorithms for the 
visualization and analysis of high-dimensional single-cell data. In Biological Sciences 
(Columbia University). 
Amir, E.-a.D., Davis, K.L., Tadmor, M.D., Simonds, E.F., Levine, J.H., Bendall, S.C., 
Shenfeld, D.K., Krishnaswamy, S., Nolan, G.P., and Pe'er, D. (2013). viSNE enables 
visualization of high dimensional single-cell data and reveals phenotypic 
heterogeneity of leukemia. Nature biotechnology 31, 545-552. 
Amsalem, H., Kwan, M., Hazan, A., Zhang, J., Jones, R.L., Whittle, W., Kingdom, 
J.C.P., Croy, B.A., Lye, S.J., and Dunk, C.E. (2014). Identification of a Novel 
Neutrophil Population: Proangiogenic Granulocytes in Second-Trimester Human 
Decidua. The Journal of Immunology 193, 3070-3079. 
Anandasabapathy, N., Victora, G.D., Meredith, M., Feder, R., Dong, B., Kluger, C., 
Yao, K., Dustin, M.L., Nussenzweig, M.C., Steinman, R.M., et al. (2011). Flt3L 
controls the development of radiosensitive dendritic cells in the meninges and choroid 
plexus of the steady-state mouse brain. The Journal of Experimental Medicine 208, 
1695-1705. 
Anderson, K.G., Mayer-Barber, K., Sung, H., Beura, L., James, B.R., Taylor, J.J., 
Qunaj, L., Griffith, T.S., Vezys, V., Barber, D.L., et al. (2014). Intravascular staining 
for discrimination of vascular and tissue leukocytes. Nature Protocols 9, 209-222. 
Arvaniti, E., and Claassen, M. (2017). Sensitive detection of rare disease-associated 
cell subsets via representation learning. Nature Communications 8, 14825. 
Aspelund, a., Antila, S., Proulx, S.T., Karlsen, T.V., Karaman, S., Detmar, M., Wiig, 
H., and Alitalo, K. (2015). A dural lymphatic vascular system that drains brain 
interstitial fluid and macromolecules. Journal of Experimental Medicine 212. 
Bandura, D.R., Baranov, V.I., Ornatsky, O.I., Antonov, A., Kinach, R., Lou, X., 
Pavlov, S., Vorobiev, S., Dick, J.E., and Tanner, S.D. (2009). Mass Cytometry: A 
Novel Technique for Real-Time Single Cell Multi-Target Immunoassay Based on 
Inductively Coupled Plasma Time of Flight Mass Spectrometry. Analytical Chemistry 
81, 6813-6822. 
	78	
Becher, B., Bechmann, I., and Greter, M. (2006). Antigen presentation in 
autoimmunity and CNS inflammation: how T lymphocytes recognize the brain. 
Journal of Molecular Medicine 84, 532-543. 
Becher, B., Durell, B.G., Miga, a.V., Hickey, W.F., and Noelle, R.J. (2001). The 
clinical course of experimental autoimmune encephalomyelitis and inflammation is 
controlled by the expression of CD40 within the central nervous system. The Journal 
of experimental medicine 193, 967-974. 
Becher, B., Durell, B.G., and Noelle, R.J. (2003). IL-23 produced by CNS-resident 
cells controls T cell encephalitogenicity during the effector phase of experimental 
autoimmune encephalomyelitis. Journal of Clinical Investigation 112, 1186-1191. 
Bechmann, I., Kwidzinski, E., Kovac, A.D., Simburger, E., Horvath, T., Gimsa, U., 
Dirnagl, U., Priller, J., and Nitsch, R. (2001). Turnover of rat brain perivascular cells. 
Experimental Neurology 168, 242-249. 
Bendall, S.C., Davis, K.L., Amir, E.A.D., Tadmor, M.D., Simonds, E.F., Chen, T.J., 
Shenfeld, D.K., Nolan, G.P., and Pe'Er, D. (2014). Single-cell trajectory detection 
uncovers progression and regulatory coordination in human b cell development. Cell 
157, 714-725. 
Bendall, S.C., Nolan, G.P., Roederer, M., and Chattopadhyay, P.K. (2012). A deep 
profiler's guide to cytometry. Trends in immunology 33, 323-332. 
Bendall, S.C., Simonds, E.F., Qiu, P., Amir, E.-a.D., Krutzik, P.O., Finck, R., 
Bruggner, R.V., Melamed, R., Trejo, A., Ornatsky, O.I., et al. (2011). Single-Cell 
Mass Cytometry of Differential Immune and Drug Responses Across a Human 
Hematopoietic Continuum. Science 332, 687-696. 
Benilova, I., Karran, E., and De Strooper, B. (2012). The toxic Abeta oligomer and 
Alzheimer's disease: an emperor in need of clothes. Nature Neuroscience 15, 349-357. 
Bruggner, R.V., Bodenmiller, B., Dill, D.L., Tibshirani, R.J., and Nolan, G.P. (2014). 
Automated identification of stratifying signatures in cellular subpopulations. 
Proceedings of the National Academy of Sciences of the United States of America 
111, E2770-2777. 
Buttgereit, A., Lelios, I., Yu, X., Vrohlings, M., Krakoski, N.R., Gautier, E.L., 
Nishinakamura, R., Becher, B., and Greter, M. (2016). Sall1 is a transcriptional 
regulator defining microglia identity and function. Nature Immunology 17, 1397-
1406. 
Checchin, D., Sennlaub, F., Levavasseur, E., Leduc, M., and Chemtob, S. (2006). 
Potential role of microglia in retinal blood vessel formation. Investigative 
Ophthalmology & Visual Science 47, 3595-3602. 
Cheng, Y., Wong, M.T., van der Maaten, L., and Newell, E.W. (2016). Categorical 
Analysis of Human T Cell Heterogeneity with One-Dimensional Soli-Expression by 
Nonlinear Stochastic Embedding. Journal of Immunology 196, 924-932. 
	79	
Chevrier, S., Crowell, H., Zanotelli, V.R.T., Engler, S., Robinson, M.D., and 
Bodenmiller, B. (2017a). Channel crosstalk correction in suspension and imaging 
mass cytometry. bioRxiv. 
Chevrier, S., Levine, J.H., Zanotelli, V.R.T., Silina, K., Schulz, D., Bacac, M., Ries, 
C.H., Ailles, L., Jewett, M.A.S., Moch, H., et al. (2017b). An Immune Atlas of Clear 
Cell Renal Cell Carcinoma. Cell 169, 736-749.e718. 
Clemente-Casares, X., Hosseinzadeh, S., Barbu, I., Dick, S.A., Macklin, J.A., Wang, 
Y., Momen, A., Kantores, C., Aronoff, L., Farno, M., et al. (2017). A CD103(+) 
Conventional Dendritic Cell Surveillance System Prevents Development of Overt 
Heart Failure during Subclinical Viral Myocarditis. Immunity 47, 974-989 e978. 
Codarri, L., Greter, M., and Becher, B. (2013). Communication between pathogenic T 
cells and myeloid cells in neuroinflammatory disease. Trends in immunology 34, 114-
119. 
Colonna, M., and Butovsky, O. (2017). Microglia Function in the Central Nervous 
System During Health and Neurodegeneration. Annual Review of Immunology 35, 
441-468. 
Compston, A., and Coles, A. (2008). Multiple sclerosis. Lancet 372, 1502-1517. 
Condello, C., Yuan, P., and Grutzendler, J. (2017). Microglia-Mediated 
Neuroprotection, TREM2, and Alzheimer's Disease: Evidence From Optical Imaging. 
Biological Psychiatry. 
Condello, C., Yuan, P., Schain, A., and Grutzendler, J. (2015). Microglia constitute a 
barrier that prevents neurotoxic protofibrillar Abeta42 hotspots around plaques. 
Nature Communications 6, 6176. 
Cossarizza, A., Chang, H.D., Radbruch, A., Andra, I., Annunziato, F., Bacher, P., 
Barnaba, V., Battistini, L., Bauer, W.M., Baumgart, S., et al. (2017). Guidelines for 
the use of flow cytometry and cell sorting in immunological studies. Eur J Immunol 
47, 1584-1797. 
Croxford, A.L., Lanzinger, M., Hartmann, F.J., Schreiner, B., Mair, F., Pelczar, P., 
Clausen, B.E., Jung, S., Greter, M., and Becher, B. (2015a). The Cytokine GM-CSF 
Drives the Inflammatory Signature of CCR2+ Monocytes and Licenses 
Autoimmunity. Immunity 43, 502-514. 
Croxford, A.L., Spath, S., and Becher, B. (2015b). GM-CSF in Neuroinflammation: 
Licensing Myeloid Cells for Tissue Damage. Trends in Immunology 36, 651-662. 
David, D.C. (2012). Aging and the aggregating proteome. Frontiers in Genetics 3, 1-
6. 
Davies, L.C., Jenkins, S.J., Allen, J.E., and Taylor, P.R. (2013). Tissue-resident 
macrophages. Nature Immunology 14, 986-995. 
Deleidi, M., Jäggle, M., and Rubino, G. (2015). Immune aging, dysmetabolism, and 
inflammation in neurological diseases. Frontiers in neuroscience 9, 172. 
	80	
Dendrou, C.A., Fugger, L., and Friese, M.A. (2015). Immunopathology of multiple 
sclerosis. Nature Reviews Immunology 15, 545-558. 
Diggins, K.E., Ferrell, P.B., and Irish, J.M. (2015). Methods for discovery and 
characterization of cell subsets in high dimensional mass cytometry data. Methods 82, 
55-63. 
Diggins, K.E., Greenplate, A.R., Leelatian, N., Wogsland, C.E., and Irish, J.M. 
(2017). Characterizing cell subsets using marker enrichment modeling. Nature 
Methods 14, 275-278. 
Elobeid, A., Libard, S., Leino, M., Popova, S.N., and Alafuzoff, I. (2016). Altered 
Proteins in the Aging Brain. Journal of Neuropathology & Experimental Neurology 
75, 316-325. 
Engelhardt, B., Vajkoczy, P., and Weller, R.O. (2017). The movers and shapers in 
immune privilege of the CNS. Nature Immunology 18, 123-131. 
Epelman, S., Lavine, K.J., Beaudin, A.E., Sojka, D.K., Carrero, J.A., Calderon, B., 
Brija, T., Gautier, E.L., Ivanov, S., Satpathy, A.T., et al. (2014). Embryonic and 
adult-derived resident cardiac macrophages are maintained through distinct 
mechanisms at steady state and during inflammation. Immunity 40. 
Everts, B., Tussiwand, R., Dreesen, L., Fairfax, K.C., Huang, S.C., Smith, A.M., 
O'Neill, C.M., Lam, W.Y., Edelson, B.T., Urban, J.F., Jr., et al. (2016). Migratory 
CD103+ dendritic cells suppress helminth-driven type 2 immunity through 
constitutive expression of IL-12. Journal of Experimental Medicine 213, 35-51. 
Fienberg, H.G., Simonds, E.F., Fantl, W.J., Nolan, G.P., and Bodenmiller, B. (2012). 
A platinum-based covalent viability reagent for single-cell mass cytometry. 
Cytometry Part A 81 A, 467-475. 
Finak, G., Perez, J.M., Weng, A., and Gottardo, R. (2010). Optimizing 
transformations for automated, high throughput analysis of flow cytometry data. 
BMC Bioinformatics 11, 546. 
Finck, R., Simonds, E.F., Jager, A., Krishnaswamy, S., Sachs, K., Fantl, W., Pe'er, D., 
Nolan, G.P., and Bendall, S.C. (2013). Normalization of mass cytometry data with 
bead standards. Cytometry Part A 83 A, 483-494. 
Fulwyler, M.J. (1965). Electronic Separation of Biological Cells by Volume. Science 
150, 910-911. 
Galea, I., Bechmann, I., and Perry, V.H. (2007). What is immune privilege (not)? 
Trends in Immunology 28, 12-18. 
Gautier, E.L., Shay, T., Miller, J., Greter, M., Jakubzick, C., Ivanov, S., Helft, J., 
Chow, A., Elpek, K.G., Gordonov, S., et al. (2012). Gene-expression profiles and 
transcriptional regulatory pathways that underlie the identity and diversity of mouse 
tissue macrophages. Nature Immunology 13, 1118-1128. 
	81	
Gentleman, R.C., Carey, V.J., Bates, D.M., Bolstad, B., Dettling, M., Dudoit, S., 
Ellis, B., Gautier, L., Ge, Y., Gentry, J., et al. (2004). Bioconductor: open software 
development for computational biology and bioinformatics. Genome Biol 5, R80. 
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., 
Conway, S.J., Ng, L.G., Stanley, E.R., et al. (2010). Fate mapping analysis reveals 
that adult microglia derive from primitive macrophages. Science (New York, NY) 
330, 841-845. 
Goldmann, T., Wieghofer, P., Jordão, M.J.C., Prutek, F., Hagemeyer, N., Frenzel, K., 
Amann, L., Staszewski, O., Kierdorf, K., Krueger, M., et al. (2016). Origin, fate and 
dynamics of macrophages at central nervous system interfaces. Nature Immunology 
17, 797-805. 
Gomez Perdiguero, E., Klapproth, K., Schulz, C., Busch, K., Azzoni, E., Crozet, L., 
Garner, H., Trouillet, C., de Bruijn, M.F., Geissmann, F., et al. (2015). Tissue-
resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors. 
Nature 518, 547-551. 
Grathwohl, S.A., Kalin, R.E., Bolmont, T., Prokop, S., Winkelmann, G., Kaeser, S.A., 
Odenthal, J., Radde, R., Eldh, T., Gandy, S., et al. (2009). Formation and maintenance 
of Alzheimer's disease beta-amyloid plaques in the absence of microglia. Nat 
Neurosci 12, 1361-1363. 
Gray, J.W., Carrano, A.V., Steinmetz, L.L., Van Dilla, M.A., Moore, D.H., Mayall, 
B.H., and Mendelsohn, M.L. (1975). Chromosome measurement and sorting by flow 
systems. Proceedings of the National Academy of Sciences 72, 1231-1234. 
Greter, M., Heppner, F.L., Lemos, M.P., Odermatt, B.M., Goebels, N., Laufer, T., 
Noelle, R.J., and Becher, B. (2005). Dendritic cells permit immune invasion of the 
CNS in an animal model of multiple sclerosis. Nature medicine 11, 328-334. 
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., 
Cruchaga, C., Sassi, C., Kauwe, J.S., Younkin, S., et al. (2013). TREM2 variants in 
Alzheimer's disease. New England Journal of Medicine 368, 117-127. 
Guilliams, M., Dutertre, C.-A., Scott, Charlotte L., McGovern, N., Sichien, D., 
Chakarov, S., Van Gassen, S., Chen, J., Poidinger, M., De Prijck, S., et al. (2016). 
Unsupervised High-Dimensional Analysis Aligns Dendritic Cells across Tissues and 
Species. Immunity 45, 669-684. 
Hanisch, U.K., and Kettenmann, H. (2007). Microglia: active sensor and versatile 
effector cells in the normal and pathologic brain. Nature Neuroscience 10, 1387-1394. 
Hartmann, F.J., Bernard-Valnet, R., Quériault, C., Mrdjen, D., Weber, L.M., Galli, E., 
Krieg, C., Robinson, M.D., Nguyen, X.-H., Dauvilliers, Y., et al. (2016). High-
dimensional single-cell analysis reveals the immune signature of narcolepsy. The 
Journal of Experimental Medicine 213, 2621-2633. 
Hawkes, C.A., and McLaurin, J. (2009). Selective targeting of perivascular 
macrophages for clearance of beta-amyloid in cerebral amyloid angiopathy. Proc Natl 
Acad Sci U S A 106, 1261-1266. 
	82	
Hellwig, S., Masuch, A., Nestel, S., Katzmarski, N., Meyer-Luehmann, M., and 
Biber, K. (2015). Forebrain microglia from wild-type but not adult 5xFAD mice 
prevent amyloid-beta plaque formation in organotypic hippocampal slice cultures. 
Science Reports 5, 14624. 
Heppner, F.L., Greter, M., Marino, D., Falsig, J., Raivich, G., Hövelmeyer, N., 
Waisman, A., Rülicke, T., Prinz, M., Priller, J., et al. (2005). Experimental 
autoimmune encephalomyelitis repressed by microglial paralysis. Nature medicine 
11, 146-152. 
Heppner, F.L., Ransohoff, R.M., and Becher, B. (2015). Immune attack: the role of 
inflammation in Alzheimer disease. Nature Reviews Neuroscience 16, 358-372. 
Herz, J., Filiano, A.J., Smith, A., Yogev, N., and Kipnis, J. (2017). Review Myeloid 
Cells in the Central Nervous System. Immunity 46, 943-956. 
Herzenberg, L.A., Tung, J., Moore, W.A., and Parks, D.R. (2006). Interpreting flow 
cytometry data: a guide for the perplexed. Nature Immunology 7, 681-685. 
Hickman, S.E., Kingery, N.D., Ohsumi, T.K., Borowsky, M.L., Wang, L.C., Means, 
T.K., and El Khoury, J. (2013). The microglial sensome revealed by direct RNA 
sequencing. Nature Neuroscience 16, 1896-1905. 
Hoeffel, G., Chen, J., Lavin, Y., Low, D., Almeida, F.F., See, P., Beaudin, A.E., Lum, 
J., Low, I., Forsberg, E.C., et al. (2015). C-Myb(+) erythro-myeloid progenitor-
derived fetal monocytes give rise to adult tissue-resident macrophages. Immunity 42, 
665-678. 
Houk, R.S., Fassel, V.A., Flesch, G.D., Svec, H.J., Gray, A.L., and Taylor, C.E. 
(1980). Inductively coupled argon plasma as an ion source for mass spectrometric 
determination of trace elements. Analytical Chemistry 52, 2283-2289. 
Idoyaga, J., Fiorese, C., Zbytnuik, L., Lubkin, A., Miller, J., Malissen, B., Mucida, D., 
Merad, M., and Steinman, R.M. (2013). Specialized role of migratory dendritic cells 
in peripheral tolerance induction. Journal of Clinical Investigation 123, 844-854. 
Jacomy, M., Venturini, T., Heymann, S., and Bastian, M. (2014). ForceAtlas2, a 
continuous graph layout algorithm for handy network visualization designed for the 
Gephi software. PLoS One 9, e98679. 
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., 
Bjornsson, S., Huttenlocher, J., Levey, A.I., Lah, J.J., et al. (2013). Variant of 
TREM2 associated with the risk of Alzheimer's disease. New England Journal of 
Medicine 368, 107-116. 
Kalaria, R.N., Premkumar, D.R.D., Pax, A.B., Cohen, D.L., and Lieberburg, I. (1996). 
Production and increased detection of amyloid β protein and amyloidogenic 
fragments in brain microvessels, meningeal vessels and choroid plexus in Alzheimer's 
disease. Molecular Brain Research 35, 58-68. 
	83	
Kang, J., Park, K.H., Kim, J.J., Jo, E.K., Han, M.K., and Kim, U.H. (2012). The role 
of CD38 in Fcγ receptor (FcγR)-mediated phagocytosis in murine macrophages. 
Journal of Biological Chemistry 287, 14502-14514. 
Keren-Shaul, H., Spinrad, A., Weiner, A., Matcovitch-Natan, O., Dvir-Szternfeld, R., 
Ulland, T.K., David, E., Baruch, K., Lara-Astaiso, D., Toth, B., et al. (2017). A 
Unique Microglia Type Associated with Restricting Development of Alzheimer’s 
Disease. Cell 169, 1276-1290.e1217. 
Kettenmann, H., Kirchhoff, F., and Verkhratsky, A. (2013). Microglia: new roles for 
the synaptic stripper. Neuron 77, 10-18. 
Kida, S., Steart, P.V., Zhang, E.-T., and Weller, R.O. (1993). Perivascular cells act as 
scavengers in the cerebral perivascular spaces and remain distinct from pericytes, 
microglia and macrophages. Acta Neuropathologica 85, 646-652. 
Kierdorf, K., Katzmarski, N., Haas, C.A., and Prinz, M. (2013). Bone marrow cell 
recruitment to the brain in the absence of irradiation or parabiosis bias. PLoS One 8, 
e58544. 
King, I.L., Kroenke, M.a., and Segal, B.M. (2010). GM-CSF-dependent, CD103+ 
dermal dendritic cells play a critical role in Th effector cell differentiation after 
subcutaneous immunization. The Journal of experimental medicine 207, 953-961. 
Kingston, D., Schmid, M.A., Onai, N., Obata-Onai, A., Baumjohann, D., and Manz, 
M.G. (2009). The concerted action of GM-CSF and Flt3-ligand on in vivo dendritic 
cell homeostasis. Blood 114, 835-843. 
Kivisäkk, P., Imitola, J., Rasmussen, S., Elyaman, W., Zhu, B., Ransohoff, R.M., and 
Khoury, S.J. (2009). Localizing central nervous system immune surveillance: 
Meningeal antigen-presenting cells activate T cells during experimental autoimmune 
encephalomyelitis. Annals of Neurology 65, 457-469. 
Kohonen, T. (1990). The self-organizing map. Proceedings of the IEEE 78, 1464-
1480. 
Koning, N., Bo, L., Hoek, R.M., and Huitinga, I. (2007). Downregulation of 
macrophage inhibitory molecules in multiple sclerosis lesions. Annals of Neurology 
62, 504-514. 
Korin, B., Ben-Shaanan, T.L., Schiller, M., Dubovik, T., Azulay-Debby, H., Boshnak, 
N.T., Koren, T., and Rolls, A. (2017). High-dimensional, single-cell characterization 
of the brain's immune compartment. Nature Neuroscience. 
Kotecha, N., Krutzik, P.O., and Irish, J.M. (2010). Web-Based Analysis and 
Publication of Flow Cytometry Experiments. In Current Protocols in Cytometry 
(Hoboken, NJ, USA: John Wiley & Sons, Inc.), pp. 1-24. 
Krasemann, S., Madore, C., Cialic, R., Baufeld, C., Calcagno, N., El Fatimy, R., 
Beckers, L., O'Loughlin, E., Xu, Y., Fanek, Z., et al. (2017). The TREM2-APOE 
Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in 
Neurodegenerative Diseases. Immunity 47, 566-581 e569. 
	84	
Levine, J.H., Simonds, E.F., Bendall, S.C., Davis, K.L., Amir, E.-a.D., Tadmor, M.D., 
Litvin, O., Fienberg, H.G., Jager, A., Zunder, E.R., et al. (2015). Data-Driven 
Phenotypic Dissection of AML Reveals Progenitor-like Cells that Correlate with 
Prognosis. Cell 162, 184-197. 
Liu, K., Victora, G.D., Schwickert, T.A., Guermonprez, P., Meredith, M.M., Yao, K., 
Chu, F.F., Randolph, G.J., Rudensky, A.Y., and Nussenzweig, M. (2009). In vivo 
analysis of dendritic cell development and homeostasis. Science 324, 392-397. 
Liu, K., Waskow, C., Liu, X., Yao, K., Hoh, J., and Nussenzweig, M. (2007). Origin 
of dendritic cells in peripheral lymphoid organs of mice. Nat Immunol 8, 578-583. 
Lodygin, D., Odoardi, F., Schlager, C., Korner, H., Kitz, A., Nosov, M., van den 
Brandt, J., Reichardt, H.M., Haberl, M., and Flugel, A. (2013). A combination of 
fluorescent NFAT and H2B sensors uncovers dynamics of T cell activation in real 
time during CNS autoimmunity. Nature Medicine 19, 784-790. 
Lou, X., Zhang, G., Herrera, I., Kinach, R., Ornatsky, O., Baranov, V., Nitz, M., and 
Winnik, M.A. (2007). Polymer-based elemental tags for sensitive bioassays. Angew 
Chem Int Ed Engl 46, 6111-6114. 
Louveau, A., Smirnov, I., Keyes, T.J., Eccles, J.D., Rouhani, S.J., Peske, J.D., 
Derecki, N.C., Castle, D., Mandell, J.W., Lee, K.S., et al. (2015). Structural and 
functional features of central nervous system lymphatic vessels. Nature 523, 337-341. 
Lucin, K.M., and Wyss-Coray, T. (2009). Immune Activation in Brain Aging and 
Neurodegeneration: Too Much or Too Little? Neuron 64, 110-122. 
Macnair, W., Roditi, L.D.V., Ganscha, S., and Claassen, M. (2017). Tree-ensemble 
analysis tests for presence of multifurcations in single cell data. bioRxiv. 
Maecker, H.T., McCoy, J.P., and Nussenblatt, R. (2012). Standardizing 
immunophenotyping for the Human Immunology Project. Nat Rev Immunol 12, 191-
200. 
Mair, F., Hartmann, F.J., Mrdjen, D., Tosevski, V., Krieg, C., and Becher, B. (2016). 
The end of gating? An introduction to automated analysis of high dimensional 
cytometry data. European Journal of Immunology 46, 34-43. 
Majonis, D., Herrera, I., Ornatsky, O., Schulze, M., Lou, X., Soleimani, M., Nitz, M., 
and Winnik, M.A. (2010). Synthesis of a functional metal-chelating polymer and 
steps toward quantitative mass cytometry bioassays. Anal Chem 82, 8961-8969. 
Majonis, D., Ornatsky, O., Kinach, R., and Winnik, M.A. (2011). Curious results with 
palladium- and platinum-carrying polymers in mass cytometry bioassays and an 
unexpected application as a dead cell stain. Biomacromolecules 12, 3997-4010. 
Majumdar, A., Chung, H., Dolios, G., Wang, R., Asamoah, N., Lobel, P., and 
Maxfield, F.R. (2008). Degradation of fibrillar forms of Alzheimer's amyloid beta-
peptide by macrophages. Neurobiology of Aging 29, 707-715. 
	85	
Maraskovsky, E., Brasel, K., Teepe, M., Roux, E.R., Lyman, S.D., Shortman, K., and 
McKenna, H.J. (1996). Dramatic increase in the numbers of functionally mature 
dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations 
identified. The Journal of experimental medicine 184, 1953-1962. 
Mato, M., Ookawara, S., Sakamoto, A., Aikawa, E., Ogawa, T., Mitsuhashi, U., 
Masuzawa, T., Suzuki, H., Honda, M., Yazaki, Y., et al. (1996). Involvement of 
specific macrophage-lineage cells surrounding arterioles in barrier and scavenger 
function in brain cortex. Proceedings of the National Academy of Sciences 93, 3269-
3274. 
Matyszak, M.K., Lawson, L.J., Perry, V.H., and Gordon, S. (1992). Stromal 
macrophages of the choroid plexus situated at an interface between the brain and 
peripheral immune system constitutively express major histocompatibility class II 
antigens. Journal of Neuroimmunology 40, 173-181. 
Matyszak, M.K., and Perry, V.H. (1996a). A comparison of leucocyte responses to 
heat-killed bacillus Calmette-Guérin in different CNS compartments. Neuropathology 
and applied neurobiology 22, 44-53. 
Matyszak, M.K., and Perry, V.H. (1996b). The potential role of dendritic cells in 
immune-mediated inflammatory diseases in the central nervous system. Neuroscience 
74, 599-608. 
McGovern, N., Shin, A., Low, G., Low, D., Duan, K., Yao, L.J., Msallam, R., Low, 
I., Shadan, N.B., Sumatoh, H.R., et al. (2017). Human fetal dendritic cells promote 
prenatal T-cell immune suppression through arginase-2. Nature. 
McMenamin, P.G. (1999). Distribution and phenotype of dendritic cells and resident 
tissue macrophages in the dura mater, leptomeninges, and choroid plexus of the rat 
brain as demonstrated in wholemount preparations. The Journal of comparative 
neurology 405, 553-562. 
Mei, H.E., Leipold, M.D., and Maecker, H.T. (2016). Platinum-conjugated antibodies 
for application in mass cytometry. Cytometry Part A 89, 292-300. 
Mei, H.E., Leipold, M.D., Schulz, a.R., Chester, C., and Maecker, H.T. (2015). 
Barcoding of Live Human Peripheral Blood Mononuclear Cells for Multiplexed Mass 
Cytometry. The Journal of Immunology 194, 2022-2031. 
Merad, M., and Manz, M.G. (2009). Review article Dendritic cell homeostasis. Cell 
113, 3418-3427. 
Merad, M., Sathe, P., Helft, J., Miller, J., and Mortha, A. (2013). The dendritic cell 
lineage: ontogeny and function of dendritic cells and their subsets in the steady state 
and the inflamed setting. Annual review of immunology 31, 563-604. 
Meyer-Luehmann, M., Spires-Jones, T.L., Prada, C., Garcia-Alloza, M., de Calignon, 
A., Rozkalne, A., Koenigsknecht-Talboo, J., Holtzman, D.M., Bacskai, B.J., and 
Hyman, B.T. (2008). Rapid appearance and local toxicity of amyloid-beta plaques in 
a mouse model of Alzheimer's disease. Nature 451, 720-724. 
	86	
Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.-K., Mack, M., 
Heikenwalder, M., Brück, W., Priller, J., and Prinz, M. (2007). Microglia in the adult 
brain arise from Ly-6ChiCCR2+ monocytes only under defined host conditions. 
Nature neuroscience 10, 1544-1553. 
Mossadegh-Keller, N., Gentek, R., Gimenez, G., Bigot, S., Mailfert, S., and Sieweke, 
M.H. (2017). Developmental origin and maintenance of distinct testicular 
macrophage populations. Journal of Experimental Medicine 214, 2829-2841. 
Mrdjen, D., Hartmann, F.J., and Becher, B. (2017). High Dimensional Cytometry of 
Central Nervous System Leukocytes During Neuroinflammation. In Inflammation: 
Methods and Protocols, B.E. Clausen, and J.D. Laman, eds. (New York, NY: Springer 
New York), pp. 321-332. 
Murphy, J.B., and Sturm, E. (1923). Conditions determining the transplantability of 
tissues in the brain. The Journal of experimental medicine 38, 183-197. 
Nimmerjahn, A., Kirchhoff, F., and Helmchen, F. (2005). Resting microglial cells are 
highly dynamic surveillants of brain parenchyma in vivo. Science 308, 1314-1318. 
Ornatsky, O., Bandura, D., Baranov, V., Nitz, M., Winnik, M.A., and Tanner, S. 
(2010). Highly multiparametric analysis by mass cytometry. Journal of 
Immunological Methods 361, 1-20. 
Ornatsky, O.I., Kinach, R., Bandura, D.R., Lou, X., Tanner, S.D., Baranov, V.I., Nitz, 
M., and Winnik, M.A. (2008). Development of analytical methods for multiplex bio-
assay with inductively coupled plasma mass spectrometry. J Anal At Spectrom 23, 
463-469. 
Owens, T., Bechmann, I., and Engelhardt, B. (2008). Perivascular spaces and the two 
steps to neuroinflammation. Journal of Neuropatholgy & Experimental Neurology 67, 
1113-1121. 
Paolicelli, R.C., Bolasco, G., Pagani, F., Maggi, L., Scianni, M., Panzanelli, P., 
Giustetto, M., Ferreira, T.A., Guiducci, E., Dumas, L., et al. (2011). Synaptic pruning 
by microglia is necessary for normal brain development. Science 333, 1456-1458. 
Parkhurst, C.N., Yang, G., Ninan, I., Savas, J.N., Yates, J.R., 3rd, Lafaille, J.J., 
Hempstead, B.L., Littman, D.R., and Gan, W.B. (2013). Microglia promote learning-
dependent synapse formation through brain-derived neurotrophic factor. Cell 155, 
1596-1609. 
Parks, D.R., Roederer, M., and Moore, W.A. (2006). A new "Logicle" display method 
avoids deceptive effects of logarithmic scaling for low signals and compensated data. 
Cytometry A 69, 541-551. 
Perfetto, S.P., Ambrozak, D., Nguyen, R., Chattopadhyay, P., and Roederer, M. 
(2006). Quality assurance for polychromatic flow cytometry. Nature Protocols 1, 
1522-1530. 
Perry, V.H., and Holmes, C. (2014). Microglial priming in neurodegenerative disease. 
Nature reviews Neurology 10, 217-224. 
	87	
Peterson, V.M., Zhang, K.X., Kumar, N., Wong, J., Li, L., Wilson, D.C., Moore, R., 
McClanahan, T.K., Sadekova, S., and Klappenbach, J.A. (2017). Multiplexed 
quantification of proteins and transcripts in single cells. Nature Biotechnology 35, 
936-939. 
Polfliet, M.M.J., van de Veerdonk, F., Döpp, E.A., van Kesteren-Hendrikx, E.M.L., 
van Rooijen, N., Dijkstra, C.D., and van den Berg, T.K. (2002). The role of 
perivascular and meningeal macrophages in experimental allergic encephalomyelitis. 
Journal of Neuroimmunology 122, 1-8. 
Prinz, M., Erny, D., and Hagemeyer, N. (2017). Ontogeny and homeostasis of CNS 
myeloid cells. Nature Immunology 18, 385. 
Prinz, M., and Priller, J. (2014). Microglia and brain macrophages in the molecular 
age: from origin to neuropsychiatric disease. Nature reviews Neuroscience 15, 300-
312. 
Pugliatti, M., Rosati, G., Carton, H., Riise, T., Drulovic, J., Vécsei, L., and Milanov, 
I. (2006). The epidemiology of multiple sclerosis in Europe. European journal of 
neurology : the official journal of the European Federation of Neurological Societies 
13, 700-722. 
Qiu, P., Simonds, E.F., Bendall, S.C., Gibbs, K.D., Jr., Bruggner, R.V., Linderman, 
M.D., Sachs, K., Nolan, G.P., and Plevritis, S.K. (2011). Extracting a cellular 
hierarchy from high-dimensional cytometry data with SPADE. Nature Biotechnology 
29, 886-891. 
Radde, R., Bolmont, T., Kaeser, S.A., Coomaraswamy, J., Lindau, D., Stoltze, L., 
Calhoun, M.E., Jaggi, F., Wolburg, H., Gengler, S., et al. (2006a). Abeta42-driven 
cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO 
Reports 7, 940-946. 
Radde, R., Bolmont, T., Kaeser, S.A., Coomaraswamy, J., Lindau, D., Stoltze, L., 
Calhoun, M.E., Jaggi, F., Wolburg, H., Gengler, S., et al. (2006b). Abeta42-driven 
cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO 
Rep 7, 940-946. 
Ransohoff, R.M., and Engelhardt, B. (2012). The anatomical and cellular basis of 
immune surveillance in the central nervous system. Nature reviews Immunology 12, 
623-635. 
Reed-Geaghan, E.G., Savage, J.C., Hise, A.G., and Landreth, G.E. (2009). CD14 and 
toll-like receptors 2 and 4 are required for fibrillar A{beta}-stimulated microglial 
activation. Journal of Neuroscience 29, 11982-11992. 
Reu, P., Khosravi, A., Bernard, S., Mold, J.E., Salehpour, M., Alkass, K., Perl, S., 
Tisdale, J., Possnert, G., Druid, H., et al. (2017). The Lifespan and Turnover of 
Microglia in the Human Brain. Cell Reports 20, 779-784. 
Robinson, J.P., and Roederer, M. (2015). Flow cytometry strikes gold. Science 350, 
739-740. 
	88	
Roumier, A., Bechade, C., Poncer, J.C., Smalla, K.H., Tomasello, E., Vivier, E., 
Gundelfinger, E.D., Triller, A., and Bessis, A. (2004). Impaired synaptic function in 
the microglial KARAP/DAP12-deficient mouse. Journal of Neuroscience 24, 11421-
11428. 
Saeys, Y., Gassen, S.V., and Lambrecht, B.N. (2016). Computational flow cytometry: 
helping to make sense of high-dimensional immunology data. Nature Reviews 
Immunology. 
Safaiyan, S., Kannaiyan, N., Snaidero, N., Brioschi, S., Biber, K., Yona, S., Edinger, 
A.L., Jung, S., Rossner, M.J., and Simons, M. (2016). Age-related myelin degradation 
burdens the clearance function of microglia during aging. Nature Neurosciience 19, 
995-998. 
Salter, M.W., and Beggs, S. (2014). Sublime microglia: expanding roles for the 
guardians of the CNS. Cell 158, 15-24. 
Samusik, N., Good, Z., Spitzer, M.H., Davis, K.L., and Nolan, G.P. (2016). 
Automated mapping of phenotype space with single-cell data. Nature Methods 13, 
493-496. 
Savina, A., and Amigorena, S. (2007). Phagocytosis and antigen presentation in 
dendritic cells. Immunological Reviews 219, 143-156. 
Schläger, C., Körner, H., Krueger, M., Vidoli, S., Haberl, M., Mielke, D., Brylla, E., 
Issekutz, T., Cabañas, C., Nelson, P.J., et al. (2016). Effector T-cell trafficking 
between the leptomeninges and the cerebrospinal fluid. Nature 530, 349-353. 
Schlitzer, A., McGovern, N., Teo, P., Zelante, T., Atarashi, K., Low, D., Ho, A.W., 
See, P., Shin, A., Wasan, P.S., et al. (2013a). IRF4 transcription factor-dependent 
CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine 
responses. Immunity 38, 970-983. 
Schlitzer, A., McGovern, N., Teo, P., Zelante, T., Atarashi, K., Low, D., Ho, A.W.S., 
See, P., Shin, A., Wasan, P.S., et al. (2013b). IRF4 transcription factor-dependent 
CD11b+ dendritic cells in human and mouse control mucosal IL-17 cytokine 
responses. Immunity 38, 970-983. 
Schlitzer, A., Sivakamasundari, V., Chen, J., Sumatoh, H.R.B., Schreuder, J., Lum, J., 
Malleret, B., Zhang, S., Larbi, A., Zolezzi, F., et al. (2015). Identification of cDC1- 
and cDC2-committed DC progenitors reveals early lineage priming at the common 
DC progenitor stage in the bone marrow. Nature Immunology, 1-13. 
Schreiner, B., Heppner, F.L., and Becher, B. (2009). Modeling multiple sclerosis in 
laboratory animals. Seminars in Immunopathology 31, 479-495. 
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., Capello, E., Mancardi, G.L., 
and Aloisi, F. (2006). Dendritic cells in multiple sclerosis lesions: maturation stage, 
myelin uptake, and interaction with proliferating T cells. Journal of neuropathology 
and experimental neurology 65, 124-141. 
	89	
Setty, M., Tadmor, M.D., Reich-Zeliger, S., Angel, O., Salame, T.M., Kathail, P., 
Choi, K., Bendall, S., Friedman, N., and Pe'er, D. (2016). Wishbone identifies 
bifurcating developmental trajectories from single-cell data. Nature Biotechnology. 
Shechter, R., London, A., and Schwartz, M. (2013a). Orchestrated leukocyte 
recruitment to immune-privileged sites: absolute barriers versus educational gates. 
Nat Rev Immunol 13, 206-218. 
Shechter, R., Miller, O., Yovel, G., Rosenzweig, N., London, A., Ruckh, J., Kim, 
K.W., Klein, E., Kalchenko, V., Bendel, P., et al. (2013b). Recruitment of Beneficial 
M2 Macrophages to Injured Spinal Cord Is Orchestrated by Remote Brain Choroid 
Plexus. Immunity 38, 555-569. 
Shirai, Y. (1921). On the transplant of the rat sarcoma in adult heterogenous animals. 
Japan Medical World, 14-15. 
Sica, A., and Mantovani, A. (2012). Macrophage plasticity and polarization: in vivo 
veritas. The Journal of Clinical Investigation 122, 787-795. 
Spath, S., Komuczki, J., Hermann, M., Pelczar, P., Mair, F., Schreiner, B., and 
Becher, B. (2017). Dysregulation of the Cytokine GM-CSF Induces Spontaneous 
Phagocyte Invasion and Immunopathology in the Central Nervous System. Immunity 
46, 245-260. 
Spitzer, M.H., Carmi, Y., Reticker-Flynn, N.E., Kwek, S.S., Madhireddy, D., Martins, 
M.M., Gherardini, P.F., Prestwood, T.R., Chabon, J., Bendall, S.C., et al. (2017). 
Systemic Immunity Is Required for Effective Cancer Immunotherapy. Cell 168, 487-
502 e415. 
Spitzer, M.H., Gherardini, P.F., Fragiadakis, G.K., Bhattacharya, N., Yuan, R.T., 
Hotson, A.N., Finck, R., Carmi, Y., Zunder, E.R., Fantl, W.J., et al. (2015). An 
interactive reference framework for modeling a dynamic immune system. Science 
349, 1259425. 
Stevens, S.M., von Gise, A., VanDusen, N., Zhou, B., and Pu, W.T. (2016). 
Epicardium is required for cardiac seeding by yolk sac macrophages, precursors of 
resident macrophages of the adult heart. Develomental Biology 413, 153-159. 
Streit, W.J., Braak, H., Xue, Q.S., and Bechmann, I. (2009). Dystrophic (senescent) 
rather than activated microglial cells are associated with tau pathology and likely 
precede neurodegeneration in Alzheimer's disease. Acta Neuropathologica 118, 475-
485. 
Streit, W.J., Sammons, N.W., Kuhns, A.J., and Sparks, D.L. (2004). Dystrophic 
microglia in the aging human brain. Glia 45, 208-212. 
Sudo, T., Nishikawa, S., Ogawa, M., Kataoka, H., Ohno, N., Izawa, A., Hayashi, S., 
and Nishikawa, S. (1995). Functional hierarchy of c-kit and c-fms in intramarrow 
production of CFU-M. Oncogene 11, 2469-2476. 
	90	
Tanner, S.D., Baranov, V.I., Ornatsky, O.I., Bandura, D.R., and George, T.C. (2013). 
An introduction to mass cytometry: fundamentals and applications. Cancer 
immunology, immunotherapy : CII 62, 955-965. 
Tremblay, M.E., Lowery, R.L., and Majewska, A.K. (2010). Microglial interactions 
with synapses are modulated by visual experience. PLoS Biol 8, e1000527. 
Trotter, J. (2007). Alternatives to log-scale data display. Current Protocols in 
Cytometry Chapter 10, Unit 10.16. 
Tussiwand, R., Everts, B., Grajales-Reyes, G., Kretzer, N., Iwata, A., Bagaitkar, J., 
Wu, X., Wong, R., Anderson, D., Murphy, T., et al. (2015). Klf4 expression in 
conventional dendritic cells is required for T helper 2 cell responses: Supplement. 
Immunity 42, 916-928. 
Ulrich, J.D., Ulland, T.K., Colonna, M., and Holtzman, D.M. (2017). Elucidating the 
Role of TREM2 in Alzheimer's Disease. Neuron 94, 237-248. 
van der Maaten, L. (2013). Barnes-Hut-SNE (ARXIV), pp. 1-11. 
Van Der Maaten, L., and Hinton, G. (2008). Visualizing Data using t-SNE. Journal of 
Machine Learning Research 9, 2579-2605. 
Van Gassen, S., Callebaut, B., Van Helden, M.J., Lambrecht, B.N., Demeester, P., 
Dhaene, T., and Saeys, Y. (2015). FlowSOM: Using self-organizing maps for 
visualization and interpretation of cytometry data. Cytometry Part A 87, 636-645. 
Vercellino, M., Trebini, C., Capello, E., Mancardi, G.L., Giordana, M.T., and Cavalla, 
P. (2017). Inflammatory responses in Multiple Sclerosis normal-appearing white 
matter and in non-immune mediated neurological conditions with wallerian axonal 
degeneration: A comparative study. J Neuroimmunol 312, 49-58. 
Vom Berg, J., Prokop, S., Miller, K.R., Obst, J., Kälin, R.E., Lopategui-Cabezas, I., 
Wegner, A., Mair, F., Schipke, C.G., Peters, O., et al. (2012). Inhibition of IL-12/IL-
23 signaling reduces Alzheimer's disease-like pathology and cognitive decline. Nature 
medicine 18, 1812-1819. 
Waskow, C., Liu, K., Darrasse-Jeze, G., Guermonprez, P., Ginhoux, F., Merad, M., 
Shengelia, T., Yao, K., and Nussenzweig, M. (2008). The receptor tyrosine kinase 
Flt3 is required for dendritic cell development in peripheral lymphoid tissues. Nat 
Immunol 9, 676-683. 
Weber, L.M., and Robinson, M.D. (2016). Comparison of clustering methods for 
high-dimensional single-cell flow and mass cytometry data. Cytometry Part A 89, 
1084-1096. 
Wynn, T.A., Chawla, A., and Pollard, J.W. (2013). Macrophage biology in 
development, homeostasis and disease. Nature 496, 445-455. 
Wyss-Coray, T. (2016). Ageing, neurodegeneration and brain rejuvenation. Nature 
539, 180-186. 
	91	
Yamasaki, R., Lu, H., Butovsky, O., Ohno, N., Rietsch, A.M., Cialic, R., Wu, P.M., 
Doykan, C.E., Lin, J., Cotleur, A.C., et al. (2014). Differential roles of microglia and 
monocytes in the inflamed central nervous system. J Exp Med 211, 1533-1549. 
Yona, S., Kim, K.W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., 
Viukov, S., Guilliams, M., Misharin, A., et al. (2013). Fate mapping reveals origins 
and dynamics of monocytes and tissue macrophages under homeostasis. Immunity 38, 
79-91. 
Yuan, P., Condello, C., Keene, C.D., Wang, Y., Bird, T.D., Paul, S.M., Luo, W., 
Colonna, M., Baddeley, D., and Grutzendler, J. (2016). TREM2 Haplodeficiency in 
Mice and Humans Impairs the Microglia Barrier Function Leading to Decreased 
Amyloid Compaction and Severe Axonal Dystrophy. Neuron 90, 724-739. 
Yuri, S., Fujimura, S., Nimura, K., Takeda, N., Toyooka, Y., Fujimura, Y., Aburatani, 
H., Ura, K., Koseki, H., Niwa, H., et al. (2009). Sall4 is essential for stabilization, but 
not for pluripotency, of embryonic stem cells by repressing aberrant trophectoderm 
gene expression. Stem Cells 27, 796-805. 
Zhan, Y., Paolicelli, R.C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., 
Vyssotski, A.L., Bifone, A., Gozzi, A., Ragozzino, D., et al. (2014). Deficient neuron-
microglia signaling results in impaired functional brain connectivity and social 
behavior. Nat Neurosci 17, 400-406. 
Zrzavy, T., Hametner, S., Wimmer, I., Butovsky, O., Weiner, H.L., and Lassmann, H. 
(2017). Loss of 'homeostatic' microglia and patterns of their activation in active 
multiple sclerosis. Brain 140, 1900-1913. 
Zunder, E.R., Finck, R., Behbehani, G.K., Amir, E.-a.D., Krishnaswamy, S., 
Gonzalez, V.D., Lorang, C.G., Bjornson, Z., Spitzer, M.H., Bodenmiller, B., et al. 
(2015a). Palladium-based mass tag cell barcoding with a doublet-filtering scheme and 
single-cell deconvolution algorithm. Nature Protocols 10, 316-333. 
Zunder, E.R., Lujan, E., Goltsev, Y., Wernig, M., and Nolan, G.P. (2015b). A 
continuous molecular roadmap to iPSC reprogramming through progression analysis 
of single-cell mass cytometry. Cell Stem Cell 16, 323-337. 
 
